




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | |
|---|--|---|--|
| (51) International Patent Classification ⁵ : C07D 307/85, 209/42, 209/22, 333/70, 401/12, 413/04, 417/04, 417/12, A61K 31/40 | | A1 | (11) International Publication Number: WO 94/29290 |
| | | | (43) International Publication Date: 22 December 1994 (22.12.94) |
| (21) International Application Number: PCT/IB94/00117 | | (81) Designated States: AU, BR, CA, CN, CZ, JP, KR, NO, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). | |
| (22) International Filing Date: 20 May 1994 (20.05.94) | | | |
| (30) Priority Data: 08/076,026 14 June 1993 (14.06.93) US | | Published With international search report. | |
| (60) Parent Application or Grant (63) Related by Continuation US 08/076,026 (CIP) Filed on 14 June 1993 (14.06.93) | | | |
| (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). | | | |
| (72) Inventors; and (75) Inventors/Applicants (for US only): DOW, Robert, L. [US/US]; 132 Shore Road, Waterford, CT 06385 (US). WRIGHT, Stephen, W. [US/US]; 1 Whitman Lane, Old Lyme, CT 06371 (US). | | | |
| (74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US). | | | |

(54) Title: SECONDARY AMINES AS ANTIDIABETIC AND ANTI-OBESITY AGENTS



(57) Abstract

The present invention relates to compounds of formula (I) having utility as hypoglycemic and antiobesity agents, methods for their use and pharmaceutical compositions containing them. The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving lean meat to fat ratio in edible animals, i.e. ungulate animals and poultry.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | GB | United Kingdom | MR | Mauritania |
| AU | Australia | GE | Georgia | MW | Malawi |
| BB | Barbados | GN | Guinea | NE | Niger |
| BE | Belgium | GR | Greece | NL | Netherlands |
| BF | Burkina Faso | HU | Hungary | NO | Norway |
| BG | Bulgaria | IE | Ireland | NZ | New Zealand |
| BJ | Benin | IT | Italy | PL | Poland |
| BR | Brazil | JP | Japan | PT | Portugal |
| BY | Belarus | KE | Kenya | RO | Romania |
| CA | Canada | KG | Kyrgyzstan | RU | Russian Federation |
| CF | Central African Republic | KP | Democratic People's Republic of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovakia |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | TJ | Tajikistan |
| DE | Germany | MD | Republic of Moldova | TT | Trinidad and Tobago |
| DK | Denmark | MG | Madagascar | UA | Ukraine |
| ES | Spain | ML | Mali | US | United States of America |
| FI | Finland | MN | Mongolia | UZ | Uzbekistan |
| FR | France | | | VN | Viet Nam |
| GA | Gabon | | | | |

-1-

5 SECONDARY AMINES AS ANTIDIABETIC AND ANTI OBESITY AGENTS Background of the Invention

The present invention relates to certain compounds of the formula (I) depicted below, having utility as hypoglycemic and antiobesity agents, methods for their use and pharmaceutical compositions containing them. The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving the lean meat to fat ratio in edible animals, i.e. ungulate animals and poultry.

The disease diabetes mellitus is characterized by metabolic defects in production and utilization of carbohydrates which result in the failure to maintain appropriate blood sugar levels. The result of these defects is elevated blood glucose or hyperglycemia. Research in the treatment of diabetes has centered on attempts to normalize fasting and postprandial blood glucose levels. Current treatments include administration of exogenous insulin, oral administration of drugs and dietary therapies.

Two major forms of diabetes mellitus are recognized. Type I diabetes, or insulin-dependent diabetes, is the result of an absolute deficiency of insulin, the hormone which regulates carbohydrate utilization. Type II diabetes, or non-insulin dependent diabetes, often occurs with normal, or even elevated levels of insulin and appears to be the result of the inability of tissues to respond appropriately to insulin. Most of the Type II diabetics are also obese.

The compounds of the present invention and the pharmaceutically active salts thereof effectively lower blood glucose levels when administered orally to mammals with hyperglycemia or diabetes.

The compounds of the present invention also decrease weight gain when administered to mammals. The ability of these compounds to affect weight gain is due to activation of β -adrenergic receptors which stimulate the metabolism of adipose tissue.


β -Adrenergic receptors can be divided into β_1 , β_2 and β_3 -subtypes. Activation of β_1 -receptors invokes increases in heart rate while activation of β_2 -receptors induces relaxation of smooth muscle tissue which produces a drop in blood pressure and the onset of smooth muscle tremors. Activation of β_3 -receptors stimulates lipolysis (the breakdown of adipose tissue triglycerides to glycerol and free fatty acids), and thereby promotes the loss of fat mass. Compounds that stimulate β_3 -receptors will have anti-obesity activity. In addition, compounds which are β_3 -adrenoceptor agonists have

-2-

hypoglycemic or anti-diabetic activity, but the mechanism of this effect is unknown. A compound that selectively stimulates β_3 -receptors, i.e., has little or no β_1 or β_2 -activity, will have the desired anti-diabetic and/or anti-obesity activity, but without the undesirable effects of increased heart rate (β_1 -effect) or muscle tremor (β_2 -effect). The use of β_3 -adrenoceptor agonists as antidiabetic, hypoglycemic and antiobesity agents has been frustrated, however, by the lack of selectivity of these agents for β_3 -adrenoceptors over the other two other adrenoceptors, β_1 and β_2 . The compounds of the present invention are selective β_3 adrenoceptor agonists.

Summary of the Invention

The present invention relates to compounds of the formula



wherein R^1 is phenyl, $-(CH_2)_n$ -O-phenyl, pyridyl, pyrimidyl or thiazolyl; wherein said phenyl and the phenyl moiety of said $-(CH_2)_n$ -O-phenyl may optionally be substituted with one or more substituents independently selected from hydrogen, (C_1-C_6) alkyl optionally substituted with one or more halo atoms, hydroxy, (C_1-C_6) alkoxy optionally substituted with one or more halo atoms, (C_1-C_6) alkylthio, fluoro, chloro, bromo, iodo, nitro, amino, $-NR^7R^8$ and cyano; and wherein each of the ring carbon atoms of said pyridyl, pyrimidinyl or thiazolyl may optionally be substituted with a substituent independently selected from hydrogen, (C_1-C_6) alkyl optionally substituted with one or more halo atoms, hydroxy, (C_1-C_6) alkoxy optionally substituted with one or more halo atoms, (C_1-C_6) alkylthio, fluoro, chloro, bromo, iodo, nitro, amino, $-NR^7R^8$ and cyano; R^2 is hydrogen or (C_1-C_6) alkyl optionally substituted with one or more halo atoms;

R^3 is hydrogen, $-(CH_2)_n$ -phenyl, $-(C_1-C_{10})$ alkyl, $-(CH_2)_n$ - NR^7R^8 , $-(CH_2)_n$ - CO_2R^2 ,

-3-

- $$\begin{array}{c} \text{O} \\ \parallel \\ -(\text{CH}_2)_n-\text{C}-\text{NR}^7\text{R}^8, \end{array}$$

$$-(\text{CH}_2)_n-\text{OR}^2, \quad -(\text{CH}_2)_n-\text{SO}_3\text{R}^2, \quad -(\text{CH}_2)_n-\text{SO}_2-(\text{C}_1-\text{C}_6)\text{alkyl}, \quad -(\text{CH}_2)_n-$$

$$\text{SO}_2\text{NR}^7\text{R}^8, \text{ or a heterocycle selected from } -(\text{CH}_2)_n\text{-pyridyl}, -(\text{CH}_2)_n\text{-pyrimidyl}, -(\text{CH}_2)_n\text{-}$$
5
$$\text{pyrazinyl}, -(\text{CH}_2)_n\text{-isoxazolyl}, -(\text{CH}_2)_n\text{-oxazolyl}, -(\text{CH}_2)_n\text{-thiazolyl}, -(\text{CH}_2)_n\text{-(1,2,4-}$$

$$\text{oxadiazolyl}), -(\text{CH}_2)_n\text{-imidazolyl}, -(\text{CH}_2)_n\text{-triazolyl and } -(\text{CH}_2)_n\text{-tetrazolyl; wherein one of}$$

$$\text{the ring nitrogen atoms of said } -(\text{CH}_2)_n\text{-imidazolyl}, -(\text{CH}_2)_n\text{-triazolyl and } -(\text{CH}_2)_n\text{-tetrazolyl}$$

$$\text{may optionally be substituted by } (\text{C}_1-\text{C}_6)\text{alkyl optionally substituted with one or more}$$

$$\text{halo atoms; wherein each of said heterocycles may optionally be substituted on one}$$
10
$$\text{or more of the ring carbon atoms by respectively, one or more substituents}$$

$$\text{independently selected from } (\text{C}_1-\text{C}_6)\text{alkyl optionally substituted with one or more halo}$$

$$\text{atoms, halo, nitro, cyano, } -(\text{CH}_2)_n-\text{NR}^7\text{R}^8, -(\text{CH}_2)_n-\text{CO}_2\text{R}^2, -(\text{CH}_2)_n-\text{C}-\text{NR}^7\text{R}^8, -(\text{CH}_2)_n-\text{OR}^2,$$

$$-(\text{CH}_2)_n-\text{SO}_2\text{R}^2, -(\text{CH}_2)_n-\text{SO}_2-(\text{C}_1-\text{C}_6)\text{alkyl, or } -(\text{CH}_2)_n-\text{SO}_2\text{NR}^7\text{R}^8; \text{ wherein the phenyl moiety}$$

$$\text{of said } -(\text{CH}_2)_n\text{-phenyl may optionally be substituted with one or more substituents,}$$
15
$$\text{independently selected from } (\text{C}_1-\text{C}_6)\text{alkyl optionally substituted with one or more halo}$$

$$\text{atoms, hydroxy, } (\text{C}_1-\text{C}_6)\text{alkoxy optionally substituted with one or more halo atoms, } (\text{C}_1-$$

$$\text{C}_6)\text{alkylthio, fluoro, chloro, bromo, iodo, cyano, nitro, } -(\text{CH}_2)_n-\text{NR}^7\text{R}^8, -(\text{CH}_2)_n-\text{CO}_2\text{R}^2,$$

$$\begin{array}{c} \text{O} \\ \parallel \\ -(\text{CH}_2)_n-\text{C}-\text{NR}^7\text{R}^8, \end{array}$$

$$-(\text{CH}_2)_n-\text{OR}^2, \quad -(\text{CH}_2)_n-\text{SO}_3\text{R}^2, \quad -(\text{CH}_2)_n-\text{SO}_2-(\text{C}_1-\text{C}_6)\text{alkyl},$$
20
$$\begin{array}{c} \text{R}^2 \\ | \\ -(\text{CH}_2)_n-\text{SO}_2\text{NR}^7\text{R}^8, \end{array}$$

$$-(\text{CH}_2)_n-\text{N}-\text{SO}_2-\text{R}^2 \text{ wherein each } \text{R}^2 \text{ is selected independently of the}$$

$$\begin{array}{c} \text{R}^2 \\ | \\ \text{other } \text{R}^2 \text{ and } -(\text{CH}_2)_n-\text{N}-\text{SO}_2-\text{NR}^7\text{R}^8; \end{array}$$
25
$$\text{R}^4 \text{ is } -(\text{CH}_2)_n-\text{CN}, -(\text{CH}_2)_n-\text{CO}_2\text{R}^2, -(\text{CH}_2)_n-\text{SO}_3\text{R}^2, -(\text{CH}_2)_n-\text{SO}_2-(\text{C}_1-\text{C}_6)\text{alkyl}, -(\text{CH}_2)_n-$$

$$\text{SO}_2-\text{NR}^7\text{R}^8, -(\text{CH}_2)_n\text{CH}_2\text{OH optionally substituted with a suitable protecting group,}$$

$$-(\text{CH}_2)_n-\text{CHO}, -(\text{CH}_2)_n-\text{C}(=\text{O})\text{R}^2, -(\text{CH}_2)_n-\text{C}(=\text{O})\text{NR}^7\text{R}^8, \text{ or a heterocycle selected from}$$

$$-(\text{CH}_2)_n\text{-thiazolyl}, -(\text{CH}_2)_n\text{-oxazolyl}, -(\text{CH}_2)_n\text{-imidazolyl}, -(\text{CH}_2)_n\text{-triazolyl}, -(\text{CH}_2)_n\text{-1,2,4-}$$

$$\text{oxadiazolyl}, -(\text{CH}_2)_n\text{-isoxazolyl}, -(\text{CH}_2)_n\text{-tetrazolyl and } -(\text{CH}_2)_n\text{-pyrazolyl; wherein one of}$$
30
$$\text{the ring nitrogen atoms of said } -(\text{CH}_2)_n\text{-imidazolyl}, -(\text{CH}_2)_n\text{-triazolyl and } -(\text{CH}_2)_n\text{-tetrazolyl}$$

$$\text{may optionally be substituted by } (\text{C}_1-\text{C}_6)\text{alkyl optionally substituted with one or more}$$

-4-

halo atoms; wherein each of said heterocycles may optionally be substituted on one or more of the ring carbon atoms by respectively, one or more substituents independently selected from hydrogen, (C₁-C₆)alkyl optionally substituted with one or

more halo atoms, -(CH₂)_n-NR⁷R⁸, -(CH₂)_n-CO₂R², halo, nitro, cyano, -(CH₂)_n-C(=O)-NR⁷R⁸,
 5 -(CH₂)_n-OR², -(CH₂)_n-SO₃R², -(CH₂)_n-SO₂-(C₁-C₆)alkyl, or -(CH₂)_n-SO₂NR⁷R⁸;

R⁵ is hydrogen or (C₁-C₆)alkyl optionally substituted with one or more halo atoms;

R⁷ and R⁸ are independently hydrogen, (C₁-C₆)alkyl optionally substituted with one or more halo, (C₁-C₆)alkoxy(C₁-C₆)alkyl or (C₃-C₈)cycloalkyl, or R⁷ and R⁸, together
 10 with the nitrogen to which they are attached, form a saturated heterocyclic ring having from 3 to 7 carbon atoms wherein one of said carbon atoms may optionally be replaced by oxygen, nitrogen or sulfur;

n is an integer from zero to six;

X is a direct link, oxygen or sulfur;

15 Y is oxygen, nitrogen or sulfur; and

Z is carbon or nitrogen; with the proviso that: (a) when Y is oxygen or sulfur, R³ is absent, and (b) when Z is nitrogen, R⁵ is absent;

or a pharmaceutically acceptable pro-drug of such compound,

or a pharmaceutically acceptable salt of such compound or pro-drug.

20 Preferred compounds of formula I are those wherein R¹ is -(CH₂)_n-O-phenyl optionally substituted with one or more substituents independently selected from hydrogen, (C₁-C₆)alkyl optionally substituted with one or more halo atoms, hydroxy, (C₁-C₆)alkoxy, (C₁-C₆)alkylthio, amino, fluoro, chloro; bromo and iodo.

Other preferred compounds of formula I are those wherein R¹ is phenyl
 25 optionally substituted with one or more substituents independently selected from hydrogen, (C₁-C₆)alkyl optionally substituted with one or more halo atoms, hydroxy, (C₁-C₆)alkoxy optionally substituted with one or more halo atoms, (C₁-C₆)alkylthio, amino, fluoro, chloro, bromo and iodo.

Other preferred compounds of formula I are those wherein R¹ is pyridyl wherein
 30 one or more of the ring carbon atoms may independently be substituted with hydrogen, (C₁-C₆)alkyl optionally substituted with one or more halo atoms, hydroxy, (C₁-C₆)alkoxy

-5-

optionally substituted with one or more halo atoms, (C₁-C₆)alkylthio, amino, fluoro, chloro, bromo and iodo.

Other preferred compounds of formula I are those wherein R¹ is phenyl, -(CH₂)-O-phenyl or pyridyl; wherein said phenyl and the phenyl moiety of said -(CH₂)_n-O-phenyl may optionally be substituted with one or more substituents; wherein one or more of the carbon atoms of said pyridyl may optionally be substituted; and wherein said substituents are independently halogen, amino or hydroxy.

Other preferred compounds of formula I are those wherein wherein X is oxygen.

Other preferred compounds of formula I are those wherein wherein X is a direct link.

Other preferred compounds of formula I are those wherein, wherein R⁴ is -CO₂CH₃, -CO₂H, -C(=O)CH₃, nitrile (-C≡N), or a heterocycle selected from 3-1,2,4-oxadiazolyl, 5-methyl-1,2,4-oxadiazolyl, 3-isoxazolyl, 3-5-methyl-isoxazolyl, 4-(2-methyl(thiazolyl)), 3-methyl-1,2,4-oxadiazolyl and 5-1,2,4-oxadiazolyl.

Other preferred compounds of formula I are those wherein, wherein R⁴ is -CO₂R².

Other preferred compounds of formula I are those wherein, wherein Y is nitrogen.

More preferred compounds of formula I are those wherein, wherein Y is nitrogen and R³ is hydrogen, methyl, ethyl, phenylmethyl, pyridylmethyl, pyrizinylmethyl or pyrimidylmethyl.

More preferred compounds of formula I are those wherein wherein R³ is hydrogen, methyl, ethyl, phenylmethyl, pyrimidylmethyl, pyrizinylmethyl or pyridylmethyl wherein each of said phenyl, pyrimidyl, pyrizinyl or pyridinyl moieties of said phenylmethyl, pyrimidylmethyl, pyrizinylmethyl, or pyridinylmethyl groups may

optionally be substituted by $\begin{array}{c} \text{R}^2 \\ | \\ -\text{SO}_2-\text{NR}^7\text{R}^8, -\text{N}-\text{SO}_2-\text{R}^2 \end{array}$ wherein each R² is

$\begin{array}{c} \text{R}^2 \\ | \\ -\text{N}-\text{SO}_2\text{NR}^7\text{R}^8. \end{array}$ selected independently of the other R² and

Examples of more preferred compounds of formula I are:

1-(5-(2(2(S)-hydroxy-3-phenoxy-propylamino)-ethoxy)-benzofuran-2-yl)-ethanone,

1-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,

- 1-(2-(2-(5-methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,
- 1-(2-(2-(2-methyl-thiazol-4-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,
- 5 1-(2-(2-(5-methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,
- 1-(2-(2-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,
- 1-benzyl-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid methyl ester, hydrochloride salt,
- 10 1-benzyl-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid,
- 1-benzyl-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester,
- 15 1-benzyl-5-(2(R,S)-(2S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid,
- 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-dimethylsulfamoyl-benzyl)-1H-indole-2-carboxylic acid ethyl ester,
- 5-(2-(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-dimethylsulfamoyl-benzyl)-1H-indole-2-carboxylic acid,
- 20 1-(4-dimethylsulfamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester,
- 1-(4-dimethylsulfamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid,
- 25 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt,
- 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid,
- 30 5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt,

-7-

5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid,

5-(2(R,S)-(2(R,S)-(6-amino-pyridin-3-yl)-2-hydroxy-ethylamino)-propyl)-1-benzyl-1H-indole-2-carboxylic acid ethyl ester,

5 5-(2(R,S)-(2(R,S)-(6-amino-pyridin-3-yl)-2-hydroxy-ethylamino)-propyl)-1-benzyl-1H-indole-2-carboxylic acid hydrochloride salt.

Examples of other preferred compounds of formula I are:

methyl 5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid,

10 methyl 5-(2(R)-(2-(2-trifluoromethyl-thiazol-4-yl)-2(R)-hydroxyethyl-amino)-propyl)-benzofuran-2-carboxylic acid,

5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid,

15 5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid, (2-methoxy-ethyl)-amide,

isopropyl 5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid,

2-bromo-1-(5-methoxy-benzofuran-2-yl)ethanone,

20 methyl 5-(2-(2(S)-hydroxy-3-(2-chlorophenoxy)-propylamino)ethoxy)-benzofuran-2-carboxylic acid,

methyl 6-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid,

6-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid,

25 methyl 5-(2-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-carboxylic acid,

5-(2-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-carboxylic acid,

30 methyl 6-(2-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-carboxylic acid,

methyl 5-(2-(2-(2-trifluoromethyl-thiazol-4-yl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-carboxylic acid,

5-(2-(2-(2-trifluoromethyl-thiazol-4-yl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-carboxylic acid,

1-(5-(2(2(S)-hydroxy-3-phenoxy-propylamino)-ethoxy)-benzofuran-2-yl)-ethanone,

1-(5-(2(2(S)-hydroxy-3-phenoxy-propylamino)-ethoxy)-benzofuran-2-yl)-butanone,

5 1-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,

1-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-3-(2-chloro-phenoxy)-propan-2(S)-ol,

1-(2-(2-(5-methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,

10 1-(2-(2-(5-methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-chloro-phenoxy)-propan-2(S)-ol,

1-(2-(2-(5-methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-fluoro-phenoxy)-propan-2(S)-ol,

15 1-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-3-(2-trifluoromethyl-phenoxy)-propan-2(S)-ol,

1-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-3-(2-cyano-phenoxy)-propan-2(S)-ol,

1-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-3-(2-fluoro-phenoxy)-propan-2(S)-ol,

20 1(R)-(3-chloro-phenyl)-2-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-ethanol,

1(R)-(3-trifluoromethyl-phenyl)-2-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-ethanol,

25 1(R)-(3-chloro-phenyl)-2-(2-(2-(5-methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol,

1(R)-(3-trifluoromethyl-phenyl)-2-(2-(2-(5-methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol,

1(R)-(3-chloro-phenyl)-2-(2-(2-(2-methyl-thiazol-4-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol,

30 1-(2-(2-(5-methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-chloro-phenoxy)-propan-2(S)-ol,

1-(2-(2-(5-methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-fluoro-phenoxy)-propan-2(S)-ol,

- 1-(2-(2-(5-trifluoromethyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,
- 1-(2-(2-(5-trifluoromethyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-chloro-phenoxy)-propan-2(S)-ol,
- 5 1-(2-(2-(5-trifluoromethyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-fluoro-phenoxy)-propan-2(S)-ol,
- 1-(2-(2-(5-ethyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,
- 1-(2-(2-(5-(2-propyl)-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,
- 10 1-(2-(2-(5-(2-phenyl)-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,
- 1-(2-(2-(5-(2-(3-pyridyl))-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol,
- 15 1-(2-(2-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-chloro-phenoxy)-propan-2(S)-ol,
- 1-(2-(2-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-fluoro-phenoxy)-propan-2(S)-ol,
- 1(R)-(3-chloro-phenyl)-2-(2-(2-(5-methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol,
- 20 1(R)-(3-trifluoro-phenyl)-2-(2-(2-(5-methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol,
- 1(R)-(2-trifluoromethyl-thiazol-4-yl)-2-(2-(2-(5-methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol,
- 25 1(R)-(3-chloro-phenyl)-2-(2-(2-(5-trifluoromethyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol,
- 1(R)-(3-chloro-phenyl)-2-(2-(2-(5-(2-propyl)-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol,
- 1(R)-(3-chloro-phenyl)-2-(2-(2-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol,
- 30 5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid, 1-propyl-amide,

- (5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-yl)-pyrrolidin-1-yl-methanone,
- (5-(2-(2(S)-hydroxy-3-(2-chloro-phenoxy)-propylamino)ethoxy)-benzofuran-2-yl)-pyrrolidin-1-yl-methanone,
- 5 (5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-indol-2-yl)-pyrrolidin-1-yl-methanone,
- (1-methyl-5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-indol-2-yl)-pyrrolidin-1-yl-methanone,
- 5-(2-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-yl)-pyrrolidin-1-yl-methanone,
- 10 5-(2(R,S)-(2-(2-trifluoromethyl-thiazol-4-yl)-2(S)-hydroxy-ethylamino)-propyl)-benzofuran-2-carboxylic acid,
- 5-(2(R)-(2-(2-trifluoromethyl-thiazol-4-yl)-2(S)-hydroxy-ethylamino)-propyl)-benzofuran-2-carboxylic acid,
- 15 4-(2(R,S)-(2-(2-trifluoromethyl-thiazol-4-yl)-2(S)-hydroxy-ethylamino)-propyl)-benzo-furan-2-carboxylic acid,
- 4-(2(R,S)-(2-(2-trifluoromethyl-thiazol-4-yl)-2(S)-hydroxy-ethylamino)-propyl)-benzo-furan-2-carboxylic acid,
- 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester,
- 20 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid,
- 5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid,
- 25 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-methyl-1H-indole-2-carboxylic acid ethyl ester,
- 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-methyl-1H-indole-2-carboxylic acid,
- 5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1-methyl-1H-indole-2-carboxylic acid,
- 30 5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-cyclopropylmethyl-1H-indole-2-carboxylic acid methyl ester,

- 5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-cyclopropylmethyl-1H-indole-2-carboxylic acid,
1-(3-carboxy-benzyl)-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid, potassium salt,
- 5 1-(3-carboxy-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid, potassium salt,
1-(4-carboxy-benzyl)-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid, potassium salt,
1-(3-carbamoyl-benzyl)-5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid, potassium salt,
- 10 1-(3-carbamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt,
1-(3-carbamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid, potassium salt,
- 15 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(3-(dimethoxy-phosphoryl)-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt,
5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(3-(dimethoxy-phosphoryl)-benzyl)-1H-indole-2-carboxylic acid,
5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(3-phosphono-benzyl)-benzyl)-1H-indole-2-carboxylic acid, hydrobromide salt,
- 20 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-(dimethoxy-phosphoryl)-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt,
5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-(dimethoxy-phosphoryl)-benzyl)-1H-indole-2-carboxylic acid,
- 25 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-phosphono-benzyl)-benzyl)-1H-indole-2-carboxylic acid,
1-(3-dimethoxy-phosphoryl)-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt,
1-(3-dimethoxy-phosphoryl)-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid,
- 30 5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1-(3-phosphono-benzyl)-1H-indole-2-carboxylic acid,

1-(4-dimethoxy-phosphoryl)-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt,

1-(4-dimethoxy-phosphoryl)-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid,

5 5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1-(4-phosphono-benzyl)-1H-indole-2-carboxylic acid, hydrobromide salt,

5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(3-dimethylcarbamoyl-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt,

10 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(3-dimethylcarbamoyl-benzyl)-1H-indole-2-carboxylic acid, potassium salt,

1-(4-dimethylcarbamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid,

5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-pyridin-4-ylmethyl-1H-indole-2-carboxylic acid methyl ester, hydrochloride salt,

15 5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-pyridin-4-ylmethyl-1H-indole-2-carboxylic acid, potassium salt,

5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-pyrimidin-4-ylmethyl-1H-indole-2-carboxylic acid,

20 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-methanesulfonyl-benzyl)-1H-indole-2-carboxylic acid methyl ester, hydrochloride salt,

5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-methanesulfonyl-benzyl)-1H-indole-2-carboxylic acid,

1-benzyl-(5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indol-2-yl)-acetic acid methyl ester, hydrochloride salt,

25 1-benzyl-(5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indol-2-yl)-acetic acid,

1-benzyl-(5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indol-2-yl)-acetic acid methyl ester, hydrochloride salt,

30 1-benzyl-(5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indol-2-yl)-acetic acid,

1-[2-(2-[1,2,4]oxadiazol-3-yl-benzo[b]thiophen-5-yloxy)-ethylamino]-3-phenoxy-propan-2(S)-ol,

-13-

- 5-[2-(2(S)-hydroxy-3-phenoxy-propylamino)-ethoxy]-benzo[b]thiophene-2-carboxylic acid,
- 5-[2-(2(S)-hydroxy-3-phenoxy-propylamino)-ethoxy]-benzo[b]thiophene-2-carboxylic acid ethyl ester,
- 5 1-[2-(2-[1,2,4]oxadiazol-3-yl-benzothiazol-6-yloxy)-ethylamino]-3-phenoxy-propan-2(S)-ol,
- 1-phenoxy-3-{2-[2-(1H-tetrazol-5-yl)-benzothiazol-6-yloxy]-ethylamino}-propan-2(S)-ol,
- 1-benzyl-5-(2(R,S)-(2(R,S)-hydroxy-2-tetrazolo(1,5-a)pyridine-6-yl-ethylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester dihydrochloride salt,
- 10 1-benzyl-5-(2(R,S)-(2(R,S)-hydroxy-2-tetrazolo(1,5-a)pyridine-6-yl-ethylamino)-propyl)-1H-indole-2-carboxylic acid,
- 5-(2(R,S)-(2(R)-hydroxy-3-phenoxy-propylamino)-propyl)-1-(2-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid.
- 15 Other compounds of formula I are:
- 1-benzyl-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid,
- 1-benzyl-5-(2-((2S)-hydroxy-3-phenoxy-propylamino)-1H-indole-2-carboxylic acid,
- 20 5-(2-((2S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid,
- (5-((2(R)-(2-(3-chloro-phenyl)-(2R)-hydroxy-ethylamino)-propyl)-benzofuran-2-yl)-acetic acid,
- 5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-indol-2-
- 25 carboxylic acid,
- 1-methyl-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-indol-2-carboxylic acid,
- 5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-benzofuran-2-carboxylic acid,
- 30 methyl-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-benzofuran-2-carboxylic acid,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-H-indole-2-carboxylic acid,

5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-H-indole-2-carboxylic acid methyl ester,

1-benzyl-5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-H-indole-2-carboxylic acid,

5 1-benzyl-5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-H-indole-2-carboxylic acid methyl ester,

5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-phenyl-1-H-indole-2-carboxylic acid,

10 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-ethyl-1-H-indole-2-carboxylic acid,

5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-ethyl-1-H-indole-2-carboxylic acid methyl ester,

5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-methyl-1-H-indole-2-carboxylic acid,

15 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-methyl-1H-indole-2-carboxylic acid methyl ester,

5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(2-hydroxyethyl)-1H-indole-2-carboxylic acid,

20 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-methanesulfonylmethyl-1H-indole-2-carboxylic acid,

5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-cyclohexylmethyl-1H-indole-2-carboxylic acid,

5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(4-pyridylmethyl)-1H-indole-2-carboxylic acid,

25 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(4-pyridylmethyl)-1H-indole-2-carboxylic acid methyl ester,

5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(3-pyridylmethyl)-1H-indole-2-carboxylic acid,

30 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(3-pyridylmethyl)-1H-indole-2-carboxylic acid methyl ester,

5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(2-pyridylmethyl)-1H-indole-2-carboxylic acid,

- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(2-pyridylmethyl)-1H-indole-2-carboxylic acid methyl ester,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-pyridinylmethyl-1H-indole-2-carboxylic acid,
- 5 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(2-methylthiazol-4-yl-methyl)-1H-indole-2-carboxylic acid,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(5-methyl-1,2,4-oxadiazol-3-yl-methyl)-1H-indole-2-carboxylic acid,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(2-pyrimidinylmethyl)-1H-indole-2-carboxylic acid,
- 10 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(2-pyrimidinylmethyl)-1H-indole-2-carboxylic acid methyl ester,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(4-pyrimidinylmethyl)-1H-indole-2-carboxylic acid,
- 15 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(4-pyrimidinylmethyl)-1H-indole-2-carboxylic acid methyl ester,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(5-pyrimidinylmethyl)-1H-indole-2-carboxylic acid,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(5-pyrimidinylmethyl)-1H-indole-2-carboxylic acid methyl ester,
- 20 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(4-(methylsulfonyl)phenylmethyl)-1H-indole-2-carboxylic acid,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-((2-carboxyphenyl)methyl)-1H-indole-2-carboxylic acid,
- 25 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(((2-carboxymethyl)phenyl)methyl)-1H-indole-2-carboxylic acid methyl ester,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-((3-carboxyphenyl)methyl)-1H-indole-2-carboxylic acid,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(((3-carboxymethyl)phenyl)methyl)-1H-indole-2-carboxylic acid methyl ester,
- 30 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-((4-carboxyphenyl)methyl)-1H-indole-2-carboxylic acid,

- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(((4-carboxymethyl)phenyl)methyl)-1H-indole-2-carboxylic acid methyl ester,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(1-imidazolylmethyl)-1H-indole-2-carboxylic acid,
- 5 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(1-imidazolylmethyl)-1H-indole-2-carboxylic acid methyl ester,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(1,2,4-triazol-4-ylmethyl)-1H-indole-2-carboxylic acid,
- 5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1-(1,2,4-triazol-4-ylmethyl)-1H-indole-2-carboxylic acid methyl ester,
- 10 1-benzyl-(5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1H-indol-2-yl)-acetic acid,
- 1-benzyl-(5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1H-indol-2-yl)-acetic acid methyl ester,
- 15 (5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1H-indol-2-yl)-acetic acid,
- (5-(2-(2-(3-chloro-phenyl)-2-hydroxy-ethylamino)-propyl)-1H-indol-2-yl)-acetic acid methyl ester,
- 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylmethyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 20 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylmethyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylmethyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 25 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylmethyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylmethyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylmethyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 30 [methanesulfonylmethyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylmethyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

- 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[4-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 10 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 15 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 20 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[3-[methanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 25 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 30 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,

- 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[3-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 10 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 15 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 20 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 25 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 30 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,

- 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[3-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 10 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 15 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 20 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 25 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[4-[trifluoromethanesulfonylamino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 30 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

10 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[3-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

15 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

20 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

25 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

30 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[4-[trifluoromethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

- 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[4-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 10 trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 15 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[4-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 20 trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[3-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 25 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 30 trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,

- 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[3-[2,2,2-trifluoroethanesulfonyl-methyl-amino]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[3-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 10 carboxylic acid,
- 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 15 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[3-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 20 indole-2-carboxylic acid,
- 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 25 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[4-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 30 benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

-23-

5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[4-sulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

10 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[3-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

15 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

20 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[3-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

25 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

30 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[4-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

-24-

5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

10 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[4-methylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

15 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[3-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

20 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

25 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[3-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

30 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[4-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 10 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-dimethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 15 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[3-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 20 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 25 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[3-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 30 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,

- 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[4-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 10 trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[4-trifluoromethylsulfamoyl-benzyl]-1H-indole-2-carboxylic acid,
- 15 5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,
- 20 trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[3-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,
- 25 5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[3-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,
- 30 trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,
- 5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[3-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,

-27-

5-[2-[2-[3-chlorophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[3-bromophenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,

5 5-[2-[2-[3-(trifluoromethyl)phenyl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-phenyl-2-hydroxy-ethylamino]-propyl]-1-[4-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,

10 5-[2-[2-[6-aminopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-amino-5-chloropyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-[6-amino-5-cyanopyridin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,

15 5-[2-[2-[6-aminopyrimidin-3-yl]-2-hydroxy-ethylamino]-propyl]-1-[4-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid,

5-[2-[2-hydroxy-3-phenoxy-propylamino]-propyl]-1-[4-[methyl-trifluoromethyl-sulfamoyl]-benzyl]-1H-indole-2-carboxylic acid.

The present invention also relates to a pharmaceutical composition for treating
20 a condition selected from the group consisting of diabetes, hyperglycemia and obesity in a mammal, comprising an amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, effective in treating such condition and a pharmaceutically acceptable carrier.

The present invention also relates to a method of treating a condition selected
25 from the group consisting of diabetes, hyperglycemia and obesity in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such condition.

The present invention also relates to a pharmaceutical composition for treating
30 a condition selected from the group consisting of diabetes, hyperglycemia and obesity in a mammal, comprising a β_3 -adrenoceptor stimulating amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


-28-

The present invention also relates to a method of treating a condition selected from the group consisting of diabetes, hyperglycemia and obesity in a mammal, comprising administering to a mammal in need of such treatment a β_3 -adrenoceptor stimulating amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.

The present invention also relates to a pharmaceutical composition for increasing the content of lean meat in edible animals, comprising a β_3 -adrenoceptor stimulating amount of a compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a method of increasing the content of lean meat in edible animals comprising administering to an edible animal a β_3 -adrenoceptor stimulating effective amount of a compound of formula I, or an acceptable salt thereof.

This invention includes prodrugs of compounds of formula I having free amino, amido, hydroxy or carboxylic groups. Prodrugs are understood to comprise an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of compounds of formula I. The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Prodrugs are also understood to include carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain. Prodrugs also include compounds in which the secondary amine and its β -hydroxy when taken together form a group of the formula



wherein n , R^1 , R^2 and X are as defined in formula I and U and V are independently carbonyl, methylene, SO_2 or SO_3 , wherein methylene is optionally substituted with hydroxy.

The present invention also relates to the pharmaceutically acceptable acid or
5 base addition salts of compounds of the formula I. The acids which are used to
prepare the pharmaceutically acceptable acid addition salts of the aforementioned base
compounds of this invention are those which form non-toxic acid addition salts, e.g.,
salts containing pharmacologically acceptable anions, such as the hydrochloride,
hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate,
10 acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate,
gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate,
p-toluenesulfonate and pamoate (i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)) salts.
Examples of pharmaceutically acceptable base addition salts are the alkali metal salts,
(e.g. sodium and potassium), alkaline earth metal salts (e.g. calcium and magnesium),
15 aluminum salts, ammonium salts, and salts with organic amines such as benzathine
(N,N'-di-benzylethylenediamine), choline, diethanolamine, ethylenediamine, meglumine
(N-methylglucamine), benethamine (N-benzylphenethylamine) diethylamine, piperazine,
tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) and procaine.

The term "halo", as used herein, unless otherwise indicated, includes chloro,
20 fluoro, bromo and iodo.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated
monovalent hydrocarbon radicals having straight, branched or cyclic moieties or
combinations thereof.

The term "one or more substituents," as used herein, includes from one to the
25 maximum number of substituents possible based on the number of available bonding
sites.

The term "treating" as used herein includes preventative treatment.

The compounds of the formula I have chiral centers and therefore exist in
different enantiomeric forms. This invention relates to all optical isomers and all
30 stereoisomers of compounds of the formula I, and mixtures thereof.

-30-

Detailed Description of the Invention

The processes and products of the present invention are illustrated in the following reaction schemes. Except where otherwise indicated, in the reaction scheme and discussion that follow, formulas I, II, III, IV, and V, and substituents R¹, R², R³, R⁴,


5 R⁵, R⁶, R⁷, R⁸, R⁹, X and halogen are defined as above.

10

15

20


-31-

SCHEME 1

10




15



20


I

-32-

SCHEME 2


-33-

SCHEME 3



-34-


SCHEME 4



-35-

SCHEME 5


5



10




15



20




25




30

-36-


SCHEME 6



VII




VIII



-37-


SCHEME 7

5



XI


10




X

15

20



XII



XIII

25

30


Scheme 1 illustrates the preparation of compounds of the formula I from aldehydes or ketones of formula III.

Referring to Scheme 1, a compound of the formula III is reacted with a compound of the formula IV to produce a compound of the formula I. This reaction is typically carried out in the presence of a reducing agent such as sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, hydrogen and a metal catalyst, zinc and hydrochloric acid, or borane dimethyl sulfide followed by treatment with formic acid. It is generally conducted at temperatures from about -60°C to about 50°C. Suitable reaction inert solvents for this reaction include lower alcohols (e.g., methanol, ethanol and isopropanol), acetic acid, chlorinated hydrocarbon solvents (e.g., methylene chloride, chloroform, 1,2 dichloroethane) and tetrahydrofuran (THF). Preferably, the solvent is 1,2-dichloroethane, the temperature is about 25°C, and the reducing agent is sodium triacetoxyborohydride.

Scheme 2 illustrates an alternative method for the preparation of compounds of formula I from amines of formula II.

Referring to Scheme 2, a compound of formula I can be synthesized from compounds of formula II by reaction with an epoxide of the formula V. This reaction is typically carried out by reacting an amine of formula II with an epoxide of formula V in a polar aprotic solvent such as dimethyl sulfoxide, dimethyl formamide, acetonitrile or a lower alkanol such as ethanol, isopropanol or butanol, at a temperature from about -10°C to about 125°C. Preferably the solvent is dimethyl sulfoxide and the reaction is run at a temperature from about 0°C to about 10°C.

A preferred modification of the above reaction involves pretreatment of the amine of formula II with N-(trimethyl-silyl)-acetamide to form a silylated compound of the formula



This reaction is typically carried out in a polar aprotic solvent such as dimethyl sulfoxide, dimethyl formamide, acetonitrile or a lower alkanol such as ethanol, isopropanol or butanol, at a temperature from about -10°C to about 125°C . Preferably, the silylation is carried out at about 25°C and the reaction with the epoxide is accomplished at about 60°C . After silylation is complete, the compound of formula XIV is reacted with the epoxide of formula V as described above.

Scheme 3 illustrates the preparation of compounds of formulae IB and IC from compounds of formula IA. Compounds of formulae IB and IC are compounds of formula I in which R^4 is CO_2H and $\text{CO}_2\text{NR}^7\text{R}^8$, respectively. Compounds of formula IA are compounds of formula I wherein R^4 is CO_2R^2 . Compounds of formula IA are prepared by the methods of Schemes 1 and 2. The transformations depicted in scheme 3 may be accomplished by methods well known to those skilled in the art.

Referring to Scheme 3, compounds of formula IA can be converted into carboxylic acids of formula IB by treatment with an acid or a base. Examples of suitable bases for the reaction are: sodium hydroxide (NaOH), potassium hydroxide (KOH), and lithium hydroxide. Suitable acids for the reaction include: hydrochloric acid (HCl), hydrobromic acid and sulfuric acid. Preferably, the base is potassium hydroxide. The solvent for the aforesaid process is typically a lower alkanol, hexane, DMF, toluene and/or water. The lower alkanol can be methanol, ethanol, propanol or butanol. The reaction temperature may range from about 0°C to about 100°C . Preferably, the temperature is about 25°C .

Compounds of formula IA can be converted into other esters of the formula IA, in which a different definition of R^2 has been substituted, by transesterification. Transesterification is facilitated by reacting a compound of formula IA with acid or base in an excess of an alcohol of the formula R^2OH . Suitable acids for the reaction include hydrochloric, hydrobromic, sulfuric and toluene sulfonic acid. Preferably, the acid is hydrochloric acid. The reaction temperature may range from about 0°C to about 115°C . Suitable solvents include alcohols of formula R^2OH , and mixtures thereof with toluene, cyclohexane, DMF and methylene chloride.

Alternatively, compounds of formula IA can be converted into amides of formula IC by treatment of the ester of formula IA with an amine of the formula $\text{R}^7\text{R}^8\text{NH}$. Usually, a polar protic solvent such as a lower alkanol is used, and the reaction is run at a temperature from about 0°C to about 125°C for about 0.5 to about 24 hours.

Suitable solvents include lower alcohols, and mixtures thereof with toluene, cyclohexane, DMF and methylene chloride. Preferably, the reaction is conducted in methanol at about 65°C for about 3 to about 24 hours.


Scheme 4 refers to the preparation of compounds of the formulae II and III, wherein X is O or S. Compounds of formulae II and III are the starting materials for the synthesis of compounds of formula I in Schemes 1 through 3. Compounds of formula III, wherein X is O or S, can be used to form compounds of formula I according to the processes of Scheme 1. Compounds of formula II, wherein X is O or S, can be used to form compounds of formula I according to the processes of Scheme 2.

Referring to Scheme 4, compounds of formula II are made by reductive amination of a compound of formula III. The conditions for reductive amination are as described above for the conversion of the ketone of formula III to the compound of formula I in Scheme I, with the exception that the amine used is ammonia or an acid addition salt thereof, instead of the amine of formula IV.

Compounds of formula III can be made in three steps beginning with compounds of the formula XV.

Compounds of the formula XV are first converted to thiols or phenols of the formula XVI by treatment of an ether (when X is O) or a thioether (when X is S) of formula XV with boron tribromide. Suitable solvents for the aforesaid reaction are non-polar aprotic solvents such as methylene chloride, toluene, chloroform, or carbon tetrachloride. Preferably, the solvent is methylene chloride. The temperature of the reaction may range from about -78°C to about 20°C during the reaction with boron tribromide. It is preferably about 0°C.

The thiol or phenol of formula XVI so formed is converted into a ketal or acetal of the formula XVII by treatment with a compound of the formula



wherein Y is chloro, bromo or iodo, in the presence of a base. Preferably, the thiol or phenol of formula XVI is first converted into an anion by reaction with a base.

Examples of appropriate bases include sodium hydride and potassium t-butoxide. The preferred base is sodium hydride (NaH). Examples of suitable solvents for the aforesaid process include polar aprotic solvents such as dimethyl formamide, dimethylsulfoxide, and sulfolane. Preferably, the solvent is dimethyl formamide.

- 5 The temperature for the aforesaid reaction is in the range of about -10°C to about 100°C. Preferably, the temperature is 30°C.

- The ketal or acetal of formula XVII so formed is converted into the corresponding compound of formula III by reaction with an acid. Typically, this reaction is conducted at a temperature in the range of about 10°C to about 100°C. Examples
10 of appropriate acids for the aforesaid process are hydrochloric, hydrobromic and sulfuric acids. Preferably, the acid is hydrochloric acid. Suitable solvents for the aforesaid process include polar solvents such as acetone and/or water. Preferably, the solvent is acetone.

- Scheme 5 refers to the preparation of compounds of the formulae III and II
15 wherein X is a direct link. Compounds of the formulae III and II are starting materials for the synthesis of the compounds of the invention illustrated in Schemes 1 through 3.


Compounds of formula III, wherein X is a direct link, can be used to form compounds of formula I according to the processes of Scheme 1.

- 20 Compounds of the formula II, wherein X is a direct link, can be used to form compounds of the formula I according to the processes of Scheme 2.

Referring to Scheme 5, compounds of the formula III can be converted into compounds of the formula II by reductive amination of a compound of the formula III with ammonia as described in Scheme 1.

- 25 Compounds of the formula III are prepared from compounds of the formula VI, by treatment of a compound of the formula VI with a tin reagent of the formula $R^2COCH_2Sn(CH_3CH_2CH_2CH_3)_3$ in the presence of palladium (II) acetate and tri-*o*-tolylphosphine. The tin reagent, $R^2COCH_2Sn(CH_3CH_2CH_2CH_3)_3$, is formed by reaction of tributyltin methoxide with a compound of the formula

-42-




5

Suitable solvents for the aforesaid process include nonpolar solvents such as toluene, benzene and hexane. Preferably, the solvent is toluene. The temperature for the aforesaid process is generally in the range of about 10°C to about 150°C, and is preferably about 95°C.

10


Scheme 6 refers to the preparation of compounds of formula IX, wherein W is bromo, -OCH₃ or -SCH₃. Compounds of formula IX wherein W is bromo are compounds of formula VI in Scheme 5, wherein R⁴ is a group of the formula

15



Compounds of formula IX wherein W is -OCH₃ or -SCH₃ are compounds of formula XV in Scheme 4, wherein X is oxygen or sulfur and R⁴ is a group of the formula

20



25

Referring to Scheme 6, a compound of formula IX is formed in two steps beginning with a compound of formula VII. The compound of formula VII is reacted with a suitable halogenating agent such as liquid bromine, N-bromosuccinimide, N-chlorosuccinimide or chlorine gas in the presence of light to form an α -haloketone of the formula VIII wherein Y is chloro, bromo or iodo. This reaction is typically carried out in a solvent such as carbon tetrachloride, chloroform or methylene chloride, preferably carbon tetrachloride, at a temperature from about 10°C to about 100°C, preferably about 30°C.

30


-43-

The α -haloketone of formula VIII is converted into the thiazole of formula IX by reaction of the α -haloketone of formula VIII with a thioamide of the formula



This reaction is typically carried out in a polar protic solvent such as a lower alkanol, DMF, DMSO, or diglyme. Suitable alcohols include methanol, ethanol, propanol and butanol. The reaction temperature may range from about 20°C to about 150°C. Preferably, the reaction is carried out in ethanol at a temperature of about 80°C.

10 Scheme 7 refers to the preparation of compounds of the formulae XI, XII and XIII wherein W is bromo, -OCH₃ or -SCH₃. Compounds of the formula XI wherein W is bromo are compounds of formula VI in Scheme 5 wherein R⁴ is



Compounds of formula XI wherein W is -OCH₃ or -SCH₃ are compounds of formula XV in Scheme 4 wherein X is oxygen or sulfur and R⁴ is




25 Compounds of formula XII wherein W is bromo are compounds of formula VI in Scheme 5 wherein R⁴ is



Compounds of formula XII wherein W is -OCH₃ or -SCH₃ are compounds of formula XV in Scheme 4 wherein X is oxygen or sulfur and R⁴ is

-44-




5 Compounds of formula XIII wherein W is bromo are compounds of formula VI in Scheme 5 wherein R⁴ is



Compounds of formula XIII wherein W is -OCH₃ or -SCH₃ are compounds of formula XV in Scheme 4 wherein X is oxygen or sulfur and R⁴ is



Referring to Scheme 7, compounds of formula X wherein R¹⁰ is -COCH₂R⁹ are
 20 converted into isoxazoles of formula XI by a two step process. Compounds of formula X are first converted into oximes of the formula



30 by treatment of the ketone of formula X with hydroxylamine in a polar solvent such as a lower alkanol and/or water. Suitable alcohols include methanol, ethanol and isopropanol. The reaction temperature may range from about 20°C to about 100°C.

-45-

The oxime of formula XVIII is converted into the isoxazole of formula XI by reaction with two equivalents of a strong base such as lithium diisopropyl amide, phenyl lithium or N-butyl lithium, followed by addition of an amide of the formula



and subsequent cyclization with hydrochloric acid in dioxane at reflux. Modifications of this process are described in G. N. Barber, Journal of Organic Chemistry, **43**, 3015-3021 (1978).

10 Scheme 7 also describes the synthesis of 3,5-disubstituted-1,2,4-oxadiazoles of formula XII from compounds of formula X, wherein R¹⁰ is an ester equivalent of formula -COR¹¹, and wherein R¹¹ is halo or alkoxy. The ester of formula X is reacted with an amidoxime of the formula



to form the oxadiazole of formula XII, according to the procedure described in Swain et al., J. Med. Chem. **34**, 140-151 (1991).

20 Scheme 7 also describes the synthesis of 3,5 disubstituted 1,2,4-oxadiazoles of formula XIII. Oxadiazoles of formula XIII can be synthesized by reacting compounds of formula X, wherein R¹⁰ is an amidoxime of the formula



with an ester equivalent (i.e. R⁹COCl) or a compound of the formula R⁹C(OR²)₃, according to the procedure of Shine et al., J. Heterocyclic Chem., **26**, 125-128 (1989).

The pharmaceutically-acceptable cation salts of the compounds of the present invention are readily prepared by reacting the acid forms with an appropriate base, usually one equivalent, in a co-solvent. Typical bases are sodium hydroxide, sodium methoxide, sodium ethoxide, sodium hydride, potassium methoxide, magnesium hydroxide, calcium hydroxide, benzathine, choline, diethanolamine, piperazine and tromethamine. The salt is isolated by concentration to dryness or by addition of a non-

30

solvent. In many cases, salts are preferably prepared by mixing a solution of the acid with a solution of a different salt of the cation (sodium or potassium ethylhexanoate, magnesium oleate), employing a solvent (e.g., ethyl acetate) from which the desired cationic salt precipitates, or can be otherwise isolated by concentration and/or addition
5 of a non-solvent.

The acid addition salts of the compounds of the present invention are readily prepared by reacting the base forms with the appropriate acid. When the salt is of a monobasic acid (e.g., the hydrochloride, the hydrobromide, the p-toluenesulfonate, the acetate), the hydrogen form of a dibasic acid (e.g., the hydrogen sulfate, the succinate)
10 or the dihydrogen form of a tribasic acid (e.g., the dihydrogen phosphate, the citrate), at least one molar equivalent and usually a molar excess of the acid is employed. However, when such salts as the sulfate, the hemisuccinate, the hydrogen phosphate or the phosphate are desired, the appropriate and exact chemical equivalents of acid will generally be used. The free base and the acid are usually combined in a co-solvent
15 from which the desired salt precipitates, or can be otherwise isolated by concentration and/or addition of a non-solvent.

The amino acid prodrugs of this invention may be prepared by conventional peptide coupling reactions coupling a free amino or carboxylic group of the compound of formula I with an amino acid or a polypeptide, e.g. dipeptide, chain. The coupling
20 reaction is generally conducted at a temperature of about -30° to about 80° C., preferably about 0° to about 25°C. Suitable coupling reagents are usually present, such as dicyclohexylcarbodiimide with hydroxybenzotriazole (HBT), N-3-dimethylaminopropyl-N'-ethylcarbodiimide with HBT, 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline, carbonyl diimidazole with HBT, or diethylphosphoryl-cyanide. The
25 reaction is generally conducted in an inert solvent such as acetonitrile, methylene chloride, chloroform, dimethylformamide, dioxane, tetrahydrofuran, dimethoxyethane, or water, or a mixture of two or more such solvents.


Ester, carbonate or carbamate prodrugs of this invention may be prepared by reaction of a free hydroxyl or amino group of the compound of formula I with an
30 activated carbonyl containing molecule such as acetyl chloride or ethyl chloroformate. The reaction can be carried out neat or in the presence of a reaction inert solvent such as methylene chloride, at a temperature from about -78° to about 100°C. Alcohols can also be reacted with cyanogen chloride in the presence of a Lewis acid to form

-47-

carbamates. Ester and amide prodrugs of free carboxylic acid groups can be made according to the methods of scheme 3.

Prodrugs in which the secondary amine and its β hydroxy, taken together, form a group of the formula

5



10

are formed by methods analogous to those described in United States Patent 4,593,023 to Beecham issued on June 3, 1986, European Patent Application 170,135A to Beecham published on July 21, 1984 and United States Patent 4,607,033 issued on August 19, 1986 to Beecham.

15

When treating diabetes mellitus and/or hyperglycemia generally satisfactory results are obtained when the compounds of the formula (I) and the pharmaceutically acceptable salts thereof (hereinafter also referred to as "the active compounds of the present invention") are administered to mammals, including man, via either the oral or the parenteral route. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or absorption following oral administration is impaired, as by disease or other abnormality, it is essential that the drug be administered parenterally. By either route, the dosage is in the range of about 0.01 to about 50 mg/kg body weight of the subject per day, preferably about 0.1 to about 25 mg/kg body weight per day, administered singly or as a divided dose. However, the optimum dosage for the individual subject being treated will be determined by the person responsible for the treatment, generally smaller doses being administered initially and thereafter increments made to determine the most suitable dosage. This will vary according to the particular compound employed and with the subject being treated.

30

When treating obesity, in conjunction with diabetes and/or hyperglycemia, or alone, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from 0.01 milligram to about 50

milligrams per kilogram of animal body weight, preferably given in divided doses 4 times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 0.1 milligrams to about 6000 milligrams, preferably from about 1 milligrams to about 1500 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 0.1 milligrams to about 1500 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.

The compounds of the present invention are used in combination with a pharmaceutically acceptable carrier or diluent. Suitable pharmaceutically-acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The active compound will be present in such pharmaceutical compositions in amounts sufficient to provide the desired dosage amount in the range described above. Thus, for oral administration the compounds can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions may, if desired, contain additional components such as flavorants, sweeteners, excipients and the like.

The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

These active compounds may also be administered parenterally. For parenteral administration the compounds can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in sesame or peanut oil, ethanol, water, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol),

suitable mixtures thereof, vegetable oils, N-methyl glucamine, polyvinylpyrrolidone and mixtures thereof in oils as well as aqueous solutions of water-soluble pharmaceutically acceptable salts of the compounds. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

- 5 The injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being the preferred parenteral route in man.

- The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of
10 sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.

- The effective dosage of the active ingredient employed may vary depending on
15 the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated.

The compounds of the present invention also possess utility for increasing lean meat deposition and/or improving lean meat to fat ratio in edible animals, i.e., ungulate animals and poultry.

- 20 Animal feed compositions effective for increasing lean meat deposition and for improving lean meat to fat ratio in poultry, swine, sheep, goats, domestic pets and cattle are generally prepared by mixing the compounds of the present invention with a sufficient amount of animal feed to provide from about 10^{-3} to 500 ppm of the compound in the feed.

- 25 Animal feed supplements can be prepared by admixing about 75% to 95% by weight of a compound of the present invention with about 5% to about 25% by weight of a suitable carrier or diluent. Carriers suitable for use to make up the feed supplement compositions include the following: alfalfa meal, soybean meal, cottonseed oil meal, linseed oil meal, sodium chloride, cornmeal, can molasses, urea, bone meal,
30 corncob meal and the like. The carrier promotes a uniform distribution of the active ingredients in the finished feed into which the supplement is blended. It thus performs an important function by ensuring proper distribution of the active ingredient throughout the feed.

-50-

If the supplement is used as a top dressing for the feed, it likewise helps to ensure uniformity of distribution of the active material across the top of the dressed feed.

The preferred medicated swine, cattle, sheep and goat feed generally contain
5 from 0.01 to 400 grams of active ingredient per ton of feed, the optimum amount for these animals usually being about 50 to 300 grams per ton of feed.

The preferred poultry and domestic pet feeds usually contain about 0.01 to 400 grams and preferably 10 to 400 grams of active ingredient per ton of feed.

For parenteral administration in animals, the compounds of the present invention
10 may be prepared in the form of a paste or a pellet and administered as an implant, usually under the skin of the head or ear of the animal in which increase in lean meat deposition and improvement in lean meat to fat ratio is sought.

In general, parenteral administration involves injection of a sufficient amount of the compounds of the present invention to provide the animal with 0.01 to 100
15 mg/kg/day of body weight of the active ingredient. The preferred dosage for swine, cattle, sheep and goats is in the range of from 0.01 to 50 mg/kg/day of body weight of active ingredient; whereas, the preferred dose level for poultry and domestic pets is usually in the range of from 0.01 to 35 mg/kg/day of body weight.

Paste formulations can be prepared by dispersing the active compound in a
20 pharmaceutically acceptable oil such as peanut oil, sesame oil, corn oil or the like.

Pellets containing an effective amount of the compounds of the present invention can be prepared by admixing the compounds of the present invention with a diluent such as carbowax, carnuba wax, and the like, and a lubricant, such as magnesium or calcium stearate, can be added to improve the pelleting process.

25 It is, of course, recognized that more than one pellet may be administered to an animal to achieve the desired dose level which will provide the increase in lean meat deposition and improvement in lean meat to fat ratio desired. Moreover, it has been found that implants may also be made periodically during the animal treatment period in order to maintain the proper drug level in the animal's body.

30 The present invention has several advantageous features. For the pet owner or veterinarian who wishes to increase leanness and trim unwanted fat from pet animals, the present invention provides the means by which this can be accomplished. For the

-51-

poultry men and swine raisers, using the method of the present invention yields leaner animals which command higher prices from the meat industry.

METHODS

The compounds of this invention may be tested for hypoglycemic activity
5 according to the following procedure.

Five to eight week old C57 BL/6J-ob/ob mice (obtained from Jackson Laboratory, Bar Harbor, Maine) are housed five per cage under standard animal care practices. After a one week acclimation period, the animals are weighed and 25 microliters of blood is collected via an ocular bleed prior to any treatment. The blood
10 sample is immediately diluted 1:5 with saline containing 2.5 mg/ml sodium fluoride and 2% sodium heparin, and held on ice for metabolite analysis. Animals are then dosed daily for five days with drug (5-50 mg/kg), a positive control (50 mg/kg) of ciglitazone; U.S. Patent 4,467,902; Sohda *et al.*, *Chem. Pharm. Bull.*, vol. 32, pp. 4460-4465, 1984), or vehicle. All drugs are administered in a vehicle consisting of 0.25% w/v methyl
15 cellulose. On day 5, the animals are weighed again and bled (via the ocular route) for blood metabolite levels. The freshly collected samples are centrifuged for two minutes at 10,000 xg at room temperature. The supernatant is analyzed for glucose, for example, by the ABA 200 Bichromatic Analyzer^{TM1}, using the A-gentTM glucose UV reagent system² (hexokinase method) using 20, 60 and 100 mg/dl standards. Plasma
20 glucose is then calculated by the equation,

$$\text{Plasma glucose (mg/dl)} = \text{Sample value} \times 5 \times 1.67 = 8.35 \times \text{Sample value}$$

where 5 is the dilution factor and 1.67 is the plasma hematocrit adjustment (assuming
25 the hematocrit is 40%).

The animals dosed with vehicle maintain substantially unchanged hyperglycemic glucose levels (e.g., 250 mg/dl), while positive control animals have depressed glucose levels (e.g., 130 mg/dl). Test compounds are reported in terms of % glucose

¹
30 ^{TMA} registered trademark of Abbott Laboratories, Diagnostics Division, 820 Mission Street, So. Pasadena, CA 91030.

²
A modification of the method of Richterrich and Dauwalder, *Schweizerische Medizinische Wochenschrift*, 101, 860 (1971).

normalization. For example, a glucose level which is the same as the positive control is reported as 100%.

Selectivity of a compound for β_3 -receptors over β_2 and β_1 receptors may be determined using the following procedures.

- 5 In vitro selectivity may be determined by measurement of cyclic Adenosine mono-phosphate (cAMP) on Chinese hamster ovary cells. Chinese hamster ovary cells uniquely transfected with the gene for the human β_1 , β_2 or β_3 receptor are grown to confluence in Ham's F12 media containing 10% fetal bovine serum, 500 μ g/ml Geneticin, 100 U/ml penicillin, 100 μ g/ml streptomycin and 250 ng/ml Fungizone.
- 10 Compounds are dissolved in Ham's F12 media, and added to the cells at 10^{-10} - 10^{-5} M along with 10^{-3} M isobutylmethylxanthine to inhibit phosphodiesterase activity. The media and cells are then incubated for 10 minutes at 37°C. At the end of this period, the media is aspirated, the cells dissolved in 0.01 N HCl and then the media is neutralized with 1 N NaOH. The cellular content of cAMP can then be determined by
- 15 Radioisotope Analysis (RIA) using a kit from New England Nuclear. There is a direct correlation between the cellular content of cAMP and the agonism of the β_3 receptor.

- In vivo efficacy and thermogenic activity may be determined by measurement of oxygen consumption and ambulatory activity on male Sprague-Dawley rats. Whole animal oxygen consumption may be measured using an open circuit, indirect
- 20 calorimeter (Oxymax™, from Columbus Instruments). The Oxymax gas sensors are calibrated with nitrogen (N_2) gas and gas mixture (0.5% carbon dioxide (CO_2), 20.5% oxygen (O_2), 79% N_2 ; Linde Specialty gases) before each experiment. Rats (male, Sprague Dawley, 300-380 g body weight) are placed in sealed chambers (43x43x10 cm) of the calorimeter and the chambers placed in activity monitors. Air flow rate through
- 25 the chambers is set at 1.6-1.7 l/min. The Oxymax calorimeter software calculates the oxygen consumption (ml/kg/h) based on the flow rate of air through the chambers and difference in oxygen content at inlet and output ports. The activity monitors have 15 infrared light beams spaced one inch apart on each axis; ambulatory activity is recorded when two consecutive beams are broken (repeated interruptions of the same
- 30 beam are not registered) and the results are recorded as counts. Basal oxygen consumption and ambulatory activity can be measured every 10 minutes for 2.5 to 3 hours. At the end of the basal period, the chambers are opened and the test compound (0.01 to 10 mg/kg, prepared in saline) or an equivalent volume of saline is

-53-

administered by oral gavage. Oxygen consumption and ambulatory activity can be measured every 10 minutes for an additional three hours post-dosing. Percent change in oxygen consumption may be calculated by averaging the post-dosing values for 2.5 hours and dividing by basal oxygen consumption (average of the predosing values except the first hour). Oxygen consumption values obtained during time periods where ambulatory activity exceeded 100 counts are excluded from the calculation. Thus, the values represent % change in resting oxygen consumption.

In vivo selectivity for β_1 and β_2 adrenoceptors may be determined by measurements of heart rate and blood pressure gathered on rats (male, Sprague Dawley, 300-380 g body weight) anesthetized with pentobarbital (50-60 mg/kg, i.p.). The left carotid artery is cannulated with PE50 tubing. The catheter is tunneled subcutaneously, exteriorized at the back of the neck, filled with a solution of polyvinylpyrrolidone in heparinized saline, flame-sealed and taped. Experiments are performed 7 days after surgery. On the day of the experiment, the catheters are untaped and flushed with saline. After at least 30 minutes, basal values for heart rate and blood pressure were measured by attaching the catheter to a pressure transducer and the results recorded on a Grass Model 7 polygraph. After obtaining basal values, the test compound or vehicle is administered by oral gavage, and blood pressure (measure of β_2 activity) and heart rate (measure of β_1 activity) measurements are taken at 15, 30, 45 and 60 minutes. To determine changes, basal values are subtracted from the average of the post dosing values.

All of the compounds of the invention were tested in the in vitro model and showed better than a four fold increase in cAMP levels at a dose of 10 nM.

The present invention is illustrated by the following Examples. However, it should be understood that the invention is not limited to the specific details of these examples.

EXAMPLES

Procedure A

Methyl 5-hydroxybenzofuran-2-carboxylic acid

To a stirred solution of ethyl 5-methoxybenzofuran-2-carboxylic acid (5.0 g, 26 mmol) in dichloromethane (CH_2Cl_2) (100 mL) at 0°C was added boron tribromide (8.6 mL, 91 mmol) and the resulting dark solution was allowed to stir at room temperature for 2 hours. The reaction solution was poured over ice, stirred for 30 minutes and extracted with ethyl acetate, (EtOAc). The organic phase was washed with water, saturated aqueous brine, dried over sodium sulfate, (Na_2SO_4), and concentrated in vacuo to afford 5-hydroxybenzofuran-2-carboxylic acid (4.0 g; m.p. $223-228^\circ\text{C}$).

Gaseous hydrochloric acid was bubbled into a cooled (0°C), stirred solution of the above acid in methanol (50 mL) over a 15-min period. The resulting solution was then refluxed for 2.5 hours, and was then cooled and concentrated in vacuo. The residue was dissolved in ethyl acetate, washed with water, brine, dried (Na_2SO_4) and concentrated in vacuo. The resulting solids were flash chromatographed on silica gel (40% ethyl acetate:hexanes) to afford the title compound as a yellow solid, (3.3 g; m.p. $164-166^\circ\text{C}$. Analytical Calculated for $\text{C}_{10}\text{H}_8\text{O}_4$: C, 62.52; H, 4.20. Found: C, 62.47; H, 4.09).

Procedure B

Methyl 5-(2,2-dimethoxyethoxy)benzofuran-2-carboxylic acid

To a stirred slurry of sodium hydride (0.11 g of 60% in oil, 2.7 mmol) in p-dioxane (10 mL) was added methyl 5-hydroxybenzofuran-2-carboxylic acid (0.5 g, 2.6 mmol) and the resulting green slurry was stirred at room temperature for 15 min. To this slurry was added a solution of bromoacetaldehyde dimethyl acetal (0.5 g, 3.0 mmol) in dimethylformamide (DMF) (10 mL) and the resulting solution was heated at reflux for 15 hours. The reaction mixture was poured into ethyl acetate, washed with water, brine, the organic phase dried (Na_2SO_4) and concentrated in vacuo. The resulting oil was flash chromatographed on silica gel (25% ethyl acetate:hexanes) to afford the title compound as a colorless solid, (0.16 g; m.p. $74-74^\circ\text{C}$).

-55-

Procedure CMethyl 5-(ethanal-2-oxy)benzofuran-2-carboxylic acid

A solution of methyl 5-(2,2-dimethoxyethoxy)benzofuran-2-carboxylic acid (0.16 g, 0.6 mmol) in acetone (4 mL) and 2 N aqueous hydrochloric acid (0.3 mL) was refluxed for 3.5 hours. The reaction solution was concentrated in vacuo, dissolved in ethyl acetate, washed with water, brine, dried (Na_2SO_4) and concentrated in vacuo to afford the title compound as a colorless solid, (0.14 g; m.p. 112-115°C).

Procedure DMethyl 5-(propan-2-one-yl)benzofuran-2-carboxylic acid

10 A solution of methyl 5-bromobenzofuran-2-carboxylic acid (2.4 g, 9.3 mmol), tributyltin methoxide (4.0 mL, 14 mmol), isopropenyl acetate (1.4 mL, 14 mmol), palladium (II) acetate (0.1 g, 0.5 mmol) and tri-*o*-tolylphosphine (0.3 g, 1 mmol) in toluene (6 mL) were heated at 95°C for 2 hours. The reaction solution was concentrated in vacuo and subjected to flash chromatography on silica gel (25% ethyl acetate:hexanes) to afford the title compound as a colorless solid, (1.8 g; m.p. 77-79°C, Analytical Calculated for $\text{C}_{13}\text{H}_{12}\text{O}_4$: C, 67.25; H, 5.21. Found: C, 67.12; H, 4.95).

Procedure E5-Methoxy-2-(2-methyl-thiazol-4-yl)-benzofuran

20 A solution of 2-bromo-1-(5-methoxy-benzofuran-2-yl)-ethanone (0.6 g, 2.2 mmol) and thioacetamide (0.4 g, 5.1 mmol) in ethanol (15 mL) were refluxed for 1 hour. The reaction mixture was concentrated in vacuo and subjected to flash chromatography on silica gel (14% ethyl acetate:hexanes) to afford the title compound as a solid, (0.47 g; m.p. 136-137°C).

25

Example 1Methyl 5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid

To a solution of methyl 5-(ethanal-2-oxy)benzofuran-2-carboxylic acid (0.13 g, 0.56 mmol) and 1-amino-3-phenoxypropan-2(S)-ol (0.10 g, 0.61 mmol) in dichloroethane (3 mL) was added glacial acetic acid (0.05 mL) and sodium triacetoxymethylborohydride (0.18 g, 0.83 mmol). After 2 hours, the reaction mixture was diluted into ethyl acetate, washed with saturated sodium bicarbonate, brine, the organic layer was dried (Na_2SO_4) and concentrated in vacuo. The resulting oil was subjected to flash chromatography

-56-

(silica gel, 5% methanol: chloroform) to afford the title compound as an off-white solid. (0.10 g; m.p. 115-119°C, Analytical Calculated for $C_{21}H_{23}NO_6 \cdot 0.25H_2O$: C, 64.70; H, 6.08; N, 3.59. Found: C, 64.89; H, 6.15; N, 3.51).

Example 2

5 Methyl 5-(2(R)-(2-(2-trifluoromethyl-thiazol-4-yl)-2(R)-hydroxyethyl-amino)-propyl)-benzofuran-2-carboxylic acid

A solution of (R)-(2-trifluoromethyl-thiazol-4-yl)-ethylene oxide (0.20 g, 1.03 mmol) and methyl 5-(2(R)-2-aminopropyl)-benzofuran-2-carboxylic acid (0.20 g, 0.86 mmol) in isopropyl alcohol (1 ml) was refluxed for 1.5 hours. After cooling, the reaction solution
10 was concentrated in vacuo and the resulting oil was flash chromatographed (silica gel, 2% methanol:chloroform) to afford the title compound as an off-white solid (0.09 g); m.p. 99-100°C.

Example 3

5-(2-(2(S)-Hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid

15 To a stirred solution of methyl 5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)-ethoxy)-benzofuran-2-carboxylic acid (0.10 g, 0.25 mmol) in methanol (5 mL) was added a solution of potassium hydroxide (42 mg, 0.75 mmol) in water (0.4 mL). After 15 hours, the reaction solution was concentrated in vacuo, the residue redissolved in water (4 mL) and the pH adjusted to between 5.0 and 5.5. The resulting solids were
20 collected washed with water, diethyl ether and dried in vacuo to afford the title compound as an off-white solid. (78 mg; m.p. 128-133°C. Analytical Calculated for $C_{20}H_{21}NO_6 \cdot 1.25H_2O$: C, 60.99; H, 6.02; N, 3.56. Found: C, 60.75; H, 5.86; N, 3.30).

Example 4

25 5-(2-(2(S)-Hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid, (2-methoxy-ethyl)-amide

A solution of methyl 5-(2-(2(S)-hydroxy-3-phenoxy-propyl-amino)ethoxy)-benzofuran-2-carboxylic acid (0.10 g, 0.26 mmol) and 2-methoxyethyl-amine (0.6 mL) in methanol (3 mL) were maintained at reflux temperature for 18 h. The reaction solution was concentrated in vacuo and flash chromatographed on silica gel (5%
30 methanol:chloroform) to afford the title compound as a colorless solid. (92 mg; m.p. 95-96°C. Analytical Calculated for $C_{23}H_{28}N_2O_6 \cdot 0.25H_2O$: C, 63.79; H, 6.63; N, 6.47. Found: C, 63.59; H, 6.39; N, 6.34.)

-57-

Example 5Isopropyl 5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid

Gaseous hydrogen chloride was slowly bubbled into a cooled (0°C), stirred
5 solution of methyl 5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid (0.1 g, 0.25 mmol) in 2-propanol (5 ml) over a 5 minute period. The resulting solution was then refluxed for 16 hours, cooled and flash chromatographed (silica gel, 5% methanol:chloroform) to afford the title compound as a colorless solid.
(0.09 g; m.p. 105-106°C. Analytical Calculated for C₂₃H₂₇NO₆: C, 66.09; H, 6.63; N, 3.35. Found: C, 66.04; H, 6.38; N, 3.31.)
10

Example 62-Bromo-1-(5-methoxy-benzofuran-2-yl)ethanone

To a cooled (0°C), stirred solution of 5-methoxy-benzofuran-2-yl chloride (prepared by treatment of 5-methoxy-benzofuran-2-carboxylic acid in refluxing thionyl
15 chloride)(4.6 g, 22 mmol) in diethyl ether (20 ml) and dichloromethane (5 ml) was added a solution of diazomethane (66 mmol) in diethyl ether (45 ml). After 15 minutes gaseous hydrogen bromide was slowly bubbled in over a 20 minute period. After an additional 30 minutes, the reaction mixture was diluted with ethyl acetate, washed with saturated aqueous brine, the organic layer dried (MgSO₄) and concentrated in vacuo.
20 The resultant red oil was flash chromatographed (silica gel, 10% ethyl acetate:hexanes) to afford the title compound as a light-yellow colored solid. 2.8 g.

M.p. 86-87°C.

Example 7Methyl 5-(2-(2(S)-hydroxy-3-(2-chlorophenoxy)-propylamino)ethoxy)-benzofuran-2-carboxylic acid
25

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 126-126.5°C.

Analytical Calculated for C₂₁H₂₂ClNO₆: C, 60.07; H, 5.28; N, 3.34. Found: C, 59.89; H, 5.22 N, 3.25.
30

-58-

Example 8Methyl 6-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid

5 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 110-111°C.

Analytical Calculated for $C_{21}H_{23}NO_6$: C, 65.36; H, 5.86; N, 3.94. Found: C, 65.44; H, 6.02; N, 3.63.

Example 9

10 6-(2-(2(S)-Hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 214-217°C.

15 Analytical Calculated for $C_{20}H_{21}NO_6 \cdot 0.25H_2O$: C, 63.90; H, 5.76; N, 3.72. Found: C, 63.53; H, 5.66; N, 3.61.

Example 10

20 Methyl 5-(2-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 104-106°C.

Analytical Calculated for $C_{20}H_{20}ClNO_5$: C, 61.62; H, 5.17; N, 3.59. Found: C, 61.44; H, 4.96; N, 3.56.

Example 11

25 5-(2-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 1.

30 M.p. 145-153°C.

-59-

Example 12Methyl 6-(2-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in
5 Example 1.

M.p. 102-103°C.

Analytical Calculated for $C_{20}H_{20}ClNO_5 \cdot 0.17H_2O$: C, 61.14; H, 5.22; N, 3.56.

Found: C, 61.02; H, 5.39; N, 3.31.

Example 13

10 Methyl 5-(2-(2-(2-trifluoromethyl-thiazol-4-yl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in
Example 1.

M.p. 128-131°C.

15 Anal. Calcd for $C_{18}H_{17}F_3N_2O_5S$: C, 50.24; H, 3.98; N, 6.51. Found: C, 50.06;
H, 3.87; N, 6.28.

Example 14

20 5-(2-(2-(2-Trifluoromethyl-thiazol-4-yl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in
Example 3.

M.p. 155-163°C. Analytical Calculated for $C_{17}H_{15}F_3N_2O_5S \cdot 2.25H_2O$: C, 44.70;
H, 4.30; N, 6.13. Found: C, 44.45; H, 4.30; N, 6.13.

Example 15

25 1-(5-(2(2(S)-Hydroxy-3-phenoxy-propylamino)-ethoxy)-benzofuran-2-yl)-ethanone

The title compound was prepared by a procedure similar to that described in
Example 1.

M.p. 122-123°C.

30 Analytical Calculated for $C_{21}H_{23}NO_5 \cdot 0.2H_2O$: C, 67.62; H, 6.32; N, 3.75. Found:
C, 67.83; H, 6.10; N, 3.73.

Example 161-(5-(2(2(S)-Hydroxy-3-phenoxy-propylamino)-ethoxy)-benzofuran-2-yl)-butanone

The title compound was prepared by a procedure similar to that described in Example 1.

- 5 M.p. 99-100°C. Analytical Calculated for $C_{23}H_{27}NO_5 \cdot 0.14H_2O$: C, 69.05; H, 6.87; N, 3.50. Found: C, 69.08; H, 6.76; N, 3.34.

Example 171-(2-(2-Isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol

- 10 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 107-110°C. Analytical Calculated for $C_{22}H_{22}N_2O_5$: C, 66.99; H, 5.62; N, 7.10. Found: C, 66.94; H, 5.42; N, 7.00.

Example 18

- 15 1-(2-(2-Isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-3-(2-chloro-phenoxy)-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 93-96°C.

- 20 Analytical Calculated for $C_{22}H_{21}ClN_2O_5 \cdot 0.25H_2O$: C, 60.97; H, 5.00; N, 6.46. Found: C, 60.99; H, 5.26; N, 5.60.

Example 19

1-(2-(2-(5-Methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol

- 25 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 144-146°C (acetone).

Analytical Calculated for $C_{23}H_{24}N_2O_5$: C, 67.63; H, 5.92; N, 6.86. Found: C, 67.65; H, 5.85; N, 6.73.

Example 20

- 30 1-(2-(2-(5-Methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-chloro-phenoxy)-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

-61-

M.p. 102-106°C.

Analytical Calculated for $C_{23}H_{23}ClN_2O_5$: C, 62.37; H, 5.23; N, 6.32. Found: C, 62.12; H, 5.58; N, 6.01.

Example 21

5 1-(2-(2-(5-Methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-fluoro-phenoxy)-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 118-121°C.

10 Analytical Calculated for $C_{23}H_{23}FN_2O_5$: C, 64.78; H, 5.44; N, 6.57. Found: C, 64.97; H, 5.38; N, 6.22.

Example 22

1-(2-(2-Isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-trifluoromethyl-phenoxy)-propan-2(S)-ol

15 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 90-91°C.

Analytical Calculated for $C_{23}H_{21}F_3N_2O_5$: C, 59.74; H, 4.58; N, 6.06. Found: C, 59.62; H, 4.49; N, 5.66.

20

Example 23

1-(2-(2-Isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-cyano-phenoxy)-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

25 M.p. 94-95°C.

Analytical Calculated for $C_{23}H_{21}N_3O_5 \cdot 0.5H_2O$: C, 64.57; H, 5.18; N, 9.81. Found: C, 64.26; H, 5.16; N, 9.35.

Example 24

30 1-(2-(2-Isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-fluoro-phenoxy)-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 109-110°C.

Analytical Calculated for $C_{22}H_{21}FN_2O_5$: C, 64.07; H, 5.13; N, 6.79. Found: C, 63.89; H, 4.98; N, 6.39.

Example 25

1(R)-(3-Chloro-phenyl)-2-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-

5 ethylamino)-ethanol

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 112-120°C.

Analytical Calculated for $C_{21}H_{19}ClN_2O_4$: C, 63.24; H, 4.57; N, 7.02. Found: C, 62.94; H, 5.13; N, 5.96.

Example 26

1(R)-(3-Trifluoromethyl-phenyl)-2-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-ethanol

The title compound was prepared by a procedure similar to that described in
15 Example 1.

M.p. 113-114°C.

Analytical Calculated for $C_{22}H_{19}F_3N_2O_4$: C, 61.11; H, 4.43; N, 6.48. Found: C, 61.48; H, 4.75; N, 5.79.

Example 27

20 1(R)-(3-Chloro-phenyl)-2-(2-(2-(5-methyl-isoxazol-3-yl)-benzofuran-
5-yloxy)-ethylamino)-ethanol

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 108-110°C.

25 Example 28

1(R)-(3-Trifluoromethyl-phenyl)-2-(2-(2-(5-methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol

The title compound was prepared by a procedure similar to that described in Example 1.

30 M.p. 126-127°C.

Analytical Calculated for $C_{23}H_{21}F_3N_2O_4$: C, 61.88; H, 4.74; N, 6.27. Found: C, 61.75; H, 4.87; N, 6.20.

-63-

Example 29

1-(2-(2-(2-Methyl-thiazol-4-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol;

The title compound was prepared by a procedure similar to that described in

5 Example 1.

M.p. 150-152°C.

Example 30

1(R)-(3-Chloro-phenyl)-2-(2-(2-(2-methyl-thiazol-4-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol

10 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 127-129°C.

Analytical Calculated for $C_{22}H_{21}ClN_2O_3S$: C, 61.60; H, 4.93; N, 6.53. Found: C, 61.54; H, 4.85; N, 6.27.

15

Example 31

1-(2-(2-(5-Methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

20

M.p. 112-114°C.

Analytical Calculated for $C_{22}H_{23}N_3O_5$: C, 64.53; H, 5.66; N, 10.26. Found: C, 64.48; H, 5.24; N, 9.97.

Example 32

25 1-(2-(2-(5-Methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-chloro-phenoxy)-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 106-108°C.

30 Anal. Calcd for $C_{22}H_{22}ClN_3O_5 \cdot 0.2H_2O$: C, 59.04; H, 5.04; N, 9.39. Found: C, 58.79; H, 4.93; N, 9.18.

-64-

Example 33

1-(2-(2-(5-Methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-fluoro-phenoxy)-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in
5 Example 1.

M.p. 102.5-103.5°C.

Anal. Calcd for $C_{22}H_{22}FN_3O_5$: C, 61.82; H, 5.19; N, 9.83. Found: C, 61.60; H, 5.21; N, 9.52.

Example 34

10 1-(2-(2-(5-Trifluoromethyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in
Example 1.

M.p. 108-113°C.

15

Example 35

1-(2-(2-(5-Trifluoromethyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-chloro-phenoxy)-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in
Example 1.

20 M.p. 112-115°C.

Analytical Calculated for $C_{22}H_{19}F_3ClN_3O_5$: C, 53.08; H, 3.85; N, 8.44. Found: C, 53.65; H, 4.08; N, 8.36.

Example 36

25 1-(2-(2-(5-Trifluoromethyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-fluoro-phenoxy)-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in
Example 1.

M.p. 117-119°C.

30 Analytical Calculated for $C_{22}H_{19}F_4N_3O_5$: C, 54.89; H, 3.98; N, 8.73. Found: C, 54.51; H, 3.84; N, 8.38.

-65-

Example 37

1-(2-(2-(5-Ethyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in

5 Example 1.

M.p. 97-98°C.

HRMS Calcd for $C_{23}H_{25}N_3O_5$: 423.1788. Found: 423.1843.

Example 38

10 1-(2-(2-(5-(2-Propyl)-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 111-112°C.

15 Analytical Calculated for $C_{24}H_{27}N_3O_5$: C, 65.89; H, 6.22; N, 9.60. Found: C, 65.61; H, 6.15; N, 9.24.

Example 39

1-(2-(2-(5-(2-Phenyl)-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol

20 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 149-151°C.

Analytical Calculated for $C_{27}H_{25}N_3O_5$: C, 68.78; H, 5.34; N, 8.91. Found: C, 68.98; H, 5.29; N, 8.82.

Example 40

25 1-(2-(2-(5-(2-(3-Pyridyl))-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 150-155°C.

-66-

Example 41

1-(2-(2-(1,2,4)-Oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol

5 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 118-119°C.

Analytical Calculated for $C_{21}H_{21}N_3O_5$: C, 63.79; H, 5.35; N, 10.63. Found: C, 63.79; H, 5.34; N, 10.62. Found: C, 63.79; H, 5.35; N, 10.63.

Example 42

10 1-(2(2-(1,2,4)-Oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-chloro-phenoxy)-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 102-104°C.

15 Analytical Calculated for $C_{21}H_{20}ClN_3O_5 \cdot 0.5H_2O$: C, 57.46; H, 4.82; N, 9.57. Found: C, 57.65; H, 4.71; N, 9.07.

Example 43

1-(2-(2-(1,2,4)-Oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-(2-fluoro-phenoxy)-propan-2(S)-ol

20 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 98-101°C.

Analytical Calculated for $C_{21}H_{20}FN_3O_5$: C, 61.01; H, 4.88; N, 10.16. Found: C, 61.39; H, 4.80; N, 9.01.

Example 44

25 1(R)-(3-Chloro-phenyl)-2-(2-(2-(5-methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol

The title compound was prepared by a procedure similar to that described in Example 1.

30 M.p. 88-92°C.

Analytical Calculated for $C_{21}H_{20}ClN_3O_4$: C, 60.94; H, 4.87; N, 10.15. Found: C, 60.95; H, 4.62; N, 9.75.

-67-

Example 45

1(R)-(3-Trifluoro-phenyl)-2-(2-(2-(5-methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol

The title compound was prepared by a procedure similar to that described in
5 Example 1.

M.p. 96-98°C.

Analytical Calculated for $C_{22}H_{20}F_3N_3O_4$: C, 59.06; H, 4.51; N, 9.39. Found: C, 58.78; H, 4.34; N, 9.17.

Example 46

10 1(R)-(2-Trifluoromethyl-thiazol-4-yl)-2-(2-(2-(5-methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol

The title compound was prepared by a procedure similar to that described in
Example 1.

M.p. 143-146°C.

15 Analytical Calculated for $C_{19}H_{17}F_3N_4O_4S$: C, 50.22; H, 3.77; N, 12.33. Found: C, 50.77; H, 3.60; N, 11.67.

Example 47

1(R)-(3-Chloro-phenyl)-2-(2-(2-(5-trifluoromethyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol

20 The title compound was prepared by a procedure similar to that described in
Example 1.

M.p. 108-111°C.

Analytical Calculated for $C_{21}H_{17}F_3ClN_3O_4$: C, 53.92; H, 3.66; N, 8.98. Found: C, 53.93; H, 3.79; N, 8.75.

25 Example 48

1(R)-(3-Chloro-phenyl)-2-(2-(2-(5-(2-propyl)-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-ethanol

The title compound was prepared by a procedure similar to that described in
Example 1.

30 M.p. 84-87°C.

Analytical Calculated for $C_{23}H_{24}ClN_3O_4$: C, 62.51; H, 5.47; N, 9.51. Found: C, 62.34; H, 5.35; N, 9.34.

-68-

Example 49

1(R)-(3-Chloro-phenyl)-2-(2-(2-(1,2,4)-oxadiazol-3-yl-benzofuran-5-yloxy)-ethylamino)-ethanol

The title compound was prepared by a procedure similar to that described in
5 Example 1.

M.p. 103-105°C.

Analytical Calculated for $C_{20}H_{18}ClN_3O_4$: C, 60.08; H, 4.54; N, 10.51. Found: C, 60.19; H, 4.42; N, 9.58.

Example 50

10 5-(2-(2(S)-Hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-carboxylic acid, 1-propyl-amide

The title compound was prepared by a procedure similar to that described in
Example 4.

M.p. 127-128°C.

15 Example 51

(5-(2-(2(S)-Hydroxy-3-phenoxy-propylamino)ethoxy)-benzofuran-2-yl)-pyrrolidin-1-yl-methanone

The title compound was prepared by a procedure similar to that described in
Example 4.

20 M.p. 117-118°C.

Analytical Calculated for $C_{24}H_{28}N_2O_5 \cdot 0.2H_2O$: C, 67.34; H, 6.69; N, 6.54. Found: C, 67.11; H, 6.24; N, 6.40.

Example 52

25 (5-(2-(2(S)-Hydroxy-3-(2-chloro-phenoxy)-propylamino)ethoxy)-benzofuran-2-yl)-pyrrolidin-1-yl-methanone

The title compound was prepared by a procedure similar to that described in
Example 4.

M.p. 89-90°C.

30 Analytical Calculated for $C_{24}H_{27}ClN_2O_5$: C, 62.80; H, 5.93; N, 6.11. Found: C, 62.59; H, 5.80; N, 5.94.

-69-

Example 53

(5-(2-(2(S)-Hydroxy-3-phenoxy-propylamino)ethoxy)-indol-2-yl)-pyrrolidin-1-yl-methanone

The title compound was prepared by a procedure similar to that described in

5 Example 4.

M.p. 110-115°C.

Example 54

(1-Methyl-5-(2-(2(S)-hydroxy-3-phenoxy-propylamino)ethoxy)-indol-2-yl)-pyrrolidin-1-yl-methanone

10 The title compound was prepared by a procedure similar to that described in Example 4.

M.p. 130-131°C.

Analytical Calculated for $C_{25}H_{31}N_3O_4 \cdot 0.5H_2O$: C, 67.23; H, 7.22; N, 9.41.

Found: C, 67.55; H, 6.98; N, 9.15.

15

Example 55

5-(2-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-ethoxy)-benzofuran-2-yl)-pyrrolidin-1-yl-methanone

The title compound was prepared by a procedure similar to that described in Example 4.

20

M.p. 96-98°C.

Analytical Calculated for $C_{23}H_{25}ClN_2O_4$: C, 64.41; H, 5.88; N, 6.53. Found: C, 64.41; H, 5.73; N, 6.19.

Example 56

25 5-(2(R,S)-(2-(2-Trifluoromethyl-thiazol-4-yl)-2(S)-hydroxy-ethylamino)-propyl)-benzofuran-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 145-163°C.

Analytical Calculated for $C_{18}H_{17}F_3N_2O_4S \cdot 1.25H_2O$: C, 49.48; H, 4.50; N, 6.41.

30 Found: C, 49.38; H, 4.56; N, 6.23.

-70-

Example 57

5-(2(R)-(2-(2-Trifluoromethyl-thiazol-4-yl)-2(S)-hydroxy-ethylamino)-propyl)-benzofuran-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in
5 Example 3.

M.p. 168-171°C.

Analytical Calculated for $C_{18}H_{17}F_3N_2O_4S \cdot 1.5H_2O$: C, 48.98; H, 4.57; N, 6.35.

Found: C, 49.04; H, 4.47; N, 6.06.

Example 58

10 4-(2(R,S)-(2-(2-Trifluoromethyl-thiazol-4-yl)-2(S)-hydroxy-ethylamino)-propyl)-benzo-furan-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in
Example 3.

M.p. 158-176°C.

15 Analytical Calculated for $C_{18}H_{17}F_3N_2O_4S \cdot 1.25H_2O$: C, 48.98; H, 4.57; N, 6.35.

Found: C, 48.87; H, 4.31; N, 6.27.

Example 59

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester

20 The title compound was prepared by a procedure similar to that described in
Example 1.

M.p. 43-44°C.

Example 60

25 5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in
Example 3.

M.p. 160-165°C.

Example 61

30 5-(2(R,S)-(2(S)-Hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in
Example 3.

-71-

M.p. 127-129°C.

Example 62

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-methyl-1H-indole-2-carboxylic acid ethyl ester

5 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. <30°C.

Analytical Calculated for $C_{23}H_{27}ClN_2O_3 \cdot 1.5 H_2O$: C, 62.51; H, 6.84; N, 6.34. Found: C, 62.51; H, 6.46; N, 5.83.

10

Example 63

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-methyl-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

15

M.p. 142-146°C.

Example 64

5-(2(R,S)-(2(S)-Hydroxy-3-phenoxy-propylamino)-propyl)-1-methyl-1H-indole-2-carboxylic acid

20 The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 98-100°C.

Example 65

5-(2(R)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-cyclopropylmethyl-1H-indole-2-carboxylic acid methyl ester

25 The title compound was prepared by a procedure similar to that described in Example 2.

M.p. 135-137°C.

Analytical Calculated for $C_{25}H_{29}ClN_2O_3$: C, 62.89; H, 6.33; N, 5.87. Found: C, 62.51; H, 6.53; N, 5.79.

30

-72-

Example 66

5-(2(R)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-cyclopropylmethyl-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in
5 Example 3.

M.p. 207-209°C.

Example 67

1-Benzyl-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid methyl ester, hydrochloride salt.

10 The title compound was prepared by a procedure similar to that described in Example 2.

M.p. 201-203°C.

Analytical Calculated for $C_{28}H_{30}ClN_2O_3$: C, 65.50; H, 5.89; N, 5.46. Found: C, 65.66; H, 6.00; N, 4.90.

15

Example 68

1-Benzyl-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

20 M.p. 128-130°C.

Example 69

1-Benzyl-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester

The title compound was prepared by a procedure similar to that described in
25 Example 1.

M.p. 168-174°C.

Analytical Calculated for $C_{30}H_{35}ClN_2O_4$: C, 68.89; H, 6.74; N, 5.36. Found: C, 68.78; H, 6.91; N, 5.01.

Example 70

30 1-Benzyl-5-(2(R,S)-(2S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

-73-

M.p. 170-181°C.

Analytical Calculated for $C_{28}H_{30}N_2O_4 \cdot 1.25H_2O$: C, 69.91; H, 6.81; N, 5.82. Found: C, 69.71; H, 6.44; N, 5.13.

Example 71

5 1-(3-Carboxy-benzyl)-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid, potassium salt.

The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 237-240°C.

10

Example 72

1-(3-Carboxy-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid, potassium salt

The title compound was prepared by a procedure similar to that described in Example 3.

15

M.p. 110-115°C.

Example 73

1-(4-Carboxy-benzyl)-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid, potassium salt

20 The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 223-225°C.

Example 74

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-dimethylsulfamoyl-benzyl)-1H-indole-2-carboxylic acid ethyl ester

25 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 122-124°C.

Analytical Calculated for $C_{31}H_{36}ClN_3O_5S \cdot 0.25H_2O$: C, 61.77; H, 6.10; N, 6.97. Found: C, 61.66; H, 6.07; N, 6.38.

30

-74-

Example 75

5-(2-(R,S)(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-dimethylsulfamoyl-benzyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in
5 Example 3.

M.p. 168-175°C.

Example 76

1-(4-Dimethylsulfamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester

10 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 112-114°C.

Analytical Calculated for $C_{32}H_{39}N_3O_6S \cdot 0.5H_2O$: C, 63.76; H, 6.69; N, 6.97. Found: C, 63.99; H, 6.58; N, 6.44.

15

Example 77

1-(4-Dimethylsulfamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

20

M.p. 148-156°C.

Analytical Calculated for $C_{30}H_{35}N_3O_6S \cdot 2.5H_2O$: C, 58.99; H, 6.60; N, 6.88. Found: 58.76; H, 6.20; N, 6.44.

Example 78

25 5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. >200°C.

30 Analytical Calculated for $C_{30}H_{35}Cl_2N_3O_5S \cdot 0.6H_2O$: C, 57.06; H, 5.77; N, 6.65. Found: C, 57.03; H, 6.00; N, 6.33.

-75-

Example 79

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in

5 Example 3.

M.p. >200°C.

Analytical Calculated for $C_{28}H_{30}Cl_2N_3O_5S \cdot 3H_2O$: C, 55.11; H, 5.94; N, 6.88. Found: C, 54.96; H, 5.41; N, 6.56.

Example 80

10 5-(2(R,S)-(2(S)-Hydroxy-3-phenoxy-propylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid ethylester, hydrochloride salt

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 61-65°C.

15 Analytical Calculated for $C_{31}H_{38}ClN_3O_6S$: C, 60.43; H, 6.22; N, 6.82. Found: C, 60.53; H, 6.22; N, 6.65.

Example 81

5-(2(R,S)-(2(S)-Hydroxy-3-phenoxy-propylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid

20 The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 180-190°C.

Analytical Calculated for $C_{29}H_{33}N_3O_6S \cdot 1.75H_2O$: C, 59.68; H, 6.00; N, 7.20. Found: C, 59.77; H, 6.02; N, 7.08.

25

Example 82

1-(3-Carbamoyl-benzyl)-5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxyethylamino)-propyl)-1H-indole-2-carboxylic acid, potassium salt

The title compound was prepared by a procedure similar to that described in Example 3.

30 M.p. 168-172°C.

-76-

Example 83

1-(3-Carbamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt

The title compound was prepared by a procedure similar to that described in

5 Example 1.

M.p. 125-128°C.

Analytical Calculated for $C_{31}H_{36}ClN_3O_5 \cdot 1H_2O$: C, 63.74; H, 6.55; N, 7.19. Found: C, 63.84; N, 6.55; N, 7.29.

Example 84

10 1-(3-Carbamoyl-benzyl)-5-(2-(R,S)(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid, potassium salt

The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 160-164°C.

15 Analytical Calculated for $C_{29}H_{30}N_3O_5K \cdot 2.5H_2O$: C, 59.57; H 6.03; N, 7.19. Found: C, 59.31; H, 5.44; N, 7.23.

Example 85

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(3-(dimethoxy-phosphoryl)-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt

20 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 110-148°C.

Analytical Calculated for $C_{31}H_{37}Cl_2N_2O_6PS$: C, 58.59; H, 5.87; N, 4.41. Found: C, 58.25; H, 6.23; N, 3.98.

25

Example 86

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(3-(dimethoxy-phosphoryl)-benzyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

30 M.p. >200°C.

-77-

Example 87

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(3-phospho-benzyl)-benzyl)-1H-indole-2-carboxylic acid, hydrobromide salt

The title compound was prepared by a procedure similar to that described in

5 Example 3.

M.p. >200°C.

Analytical Calculated for $C_{27}H_{28}BrClN_2O_6P \cdot 2.5H_2O$: C, 48.47; H, 4.97; N, 4.19. Found: C, 48.27; H, 5.17; N, 4.22.

Example 88

10 5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-(dimethoxy-phosphoryl)-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 90-105°C.

15

Example 89

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-(dimethoxy-phosphoryl)-benzyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

20

M.p. 218-220°C.

Analytical Calculated for $C_{29}H_{32}N_2O_6P \cdot 2.5H_2O$: C, 56.50; H, 5.23; N, 4.54. Found: C, 56.15; H, 5.39; N, 4.65.

Example 90

25 5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-phospho-benzyl)-benzyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

M.p. >200°C.

Example 91

30 1-(3-Dimethoxy-phosphoryl)-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt

The title compound was prepared by a procedure similar to that described in Example 1.

-78-

M.p. 118-132°C.

Analytical Calculated for $C_{32}H_{39}N_2O_7P \cdot 0.5H_2O$: C, 60.04; H, 6.29; N, 4.38. Found: C, 60.17; H, 6.64; N, 4.45.

Example 92

- 5 1-(3-Dimethoxy-phosphoryl)-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 173-180°C.

- 10 Analytical Calculated for $CH_{35}N_2O_7P \cdot 1.3H_2O$: C, 61.00; H, 6.37; N, 4.74. Found: C, 61.05; H, 6.40; N, 4.90.

Example 93

5-(2(R,S)-(2(S)-Hydroxy-3-phenoxy-propylamino)-propyl)-1-(3-phosphono-benzyl)-1H-indole-2-carboxylic acid

- 15 The title compound was prepared by a procedure similar to that described in Example 3.

M.p. >200°C.

Analytical Calculated for $C_{28}H_{32}BrN_2O_7P \cdot 3.2H_2O$: C, 49.66; H, 5.57; N, 4.14. Found: C, 49.42; H, 5.62; N, 4.66.

20

Example 94

1-(4-Dimethoxy-phosphoryl)-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt

The title compound was prepared by a procedure similar to that described in Example 1.

25

M.p. 75-85°C.

Example 95

1-(4-Dimethoxy-phosphoryl)-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid

- 30 The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 188-192°C.

Analytical Calculated for $C_{30}H_{35}N_2O_7P \cdot 1H_2O$: C, 61.63; H, 6.37; N, 4.79. Found: C, 61.24; H, 6.37; N, 4.87.

-79-

Example 96

5-(2(R,S)-(2(S)-Hydroxy-3-phenoxy-propylamino)-propyl)-1-(4-phospho-benzyl)-1H-indole-2-carboxylic acid, hydrobromide salt

The title compound was prepared by a procedure similar to that described in
5 Example 1.

M.p. 130-135°C.

Example 97

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(3-dimethylcarbamoyl-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt

10 The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 94-96°C.

Analytical Calculated for $C_{32}H_{37}Cl_2N_3O_4 \cdot 0.5H_2O$: C, 63.26; H, 6.30; N, 6.91. Found: C, 62.87; H, 6.26; N, 6.74.

15 Example 98

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(3-dimethylcarbamoyl-benzyl)-1H-indole-2-carboxylic acid, potassium salt

The title compound was prepared by a procedure similar to that described in Example 3.

20 M.p. 72-75°C.

Analytical Calculated for $C_{30}H_{31}ClN_3O_4K \cdot 3H_2O$: C, 57.54; H, 5.96; N, 6.71. Found: C, 57.24; H, 5.66; N, 6.57.

Example 99

25 1-(4-Dimethylcarbamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 94-97°C.

30 Analytical Calculated for $C_{31}H_{34}N_3O_5 \cdot 2.5H_2O$: C, 60.76; H, 6.42; N, 6.86. Found: C, 60.61; H, 5.84; N, 6.73.

Example 100

5-(2(R)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-pyridin-4-ylmethyl-1H-indole-2-carboxylic acid methyl ester, hydrochloride salt

The title compound was prepared by a procedure similar to that described in

5 Example 2.

M.p. 85-88°C.

Example 101

5-(2(R)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-pyridin-4-ylmethyl-1H-indole-2-carboxylic acid, potassium salt

10 The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 188-190°C.

Example 102

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-pyrimidin-4-ylmethyl-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 158-161°C.

Analytical Calculated for $C_{25}H_{25}ClN_4O_3 \cdot 1H_2O$: C, 61.21; H, 5.78; N, 11.90. Found: C, 61.39; H, 5.71; N, 10.76.

Example 103

5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-methanesulfonyl-benzyl)-1H-indole-2-carboxylic acid methyl ester, hydrochloride salt

The title compound was prepared by a procedure similar to that described in

25 Example 1.

M.p. 196-197°C.

Analytical Calculated for $C_{29}H_{31}ClN_2O_5S$: C, 58.88; H, 5.45; N, 4.74. Found: C, 58.56; H, 5.43; N, 4.44.

Example 104

30 5-(2(R,S)-(2-(3-Chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-methanesulfonyl-benzyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

-81-

M.p. 150-155°C.

Example 105

1-Benzyl-(5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indol-2-yl)-acetic acid methyl ester, hydrochloride salt

5 The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 137-142°C.

Analytical Calculated for $C_{29}H_{32}Cl_2N_2O_3 \cdot 0.25H_2O$: C, 65.46; H, 6.11; N, 5.27. Found: C, 65.58; H, 6.11; N, 5.18.

10

Example 106

1-Benzyl-(5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indol-2-yl)-acetic acid

The title compound was prepared by a procedure similar to that described in Example 3.

15

M.p. 131-141°C.

Analytical Calculated for $C_{28}H_{29}ClN_2O_3 \cdot 1.25H_2O$: C, 67.35; H, 6.10; N, 5.61. Found: C, 67.35; H, 6.29; N, 5.56.

Example 107

20 1-Benzyl-(5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indol-2-yl)-acetic acid methyl ester, hydrochloride salt

The title compound was prepared by a procedure similar to that described in Example 1.

M.p. 162-175°C.

25 Analytical Calculated for $C_{30}H_{34}N_2O_4 \cdot 1H_2O$: C, 66.59; H, 6.71; N, 5.18. Found: C, 66.44; H, 6.81; N, 5.21.

Example 108

1-Benzyl-(5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indol-2-yl)-acetic acid

30 The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 153-158°C.

Analytical Calculated for $C_{29}H_{32}N_2O_4 \cdot 0.6H_2O$: C, 72.04; H, 6.92; N, 5.79. Found: C, 72.35; H, 7.00; N, 5.65.

Example 1091-[2-(2-[1,2,4]Oxadiazol-3-yl-benzo[b]thiophen-5-yloxy)-ethylamino]-3-phenoxy-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in
5 Example 1.

M.p. 101-102°C.

Analytical Calculated for $C_{21}H_{21}N_3O_4S$: C, 61.30; H, 5.14; N 10.21. Found: C, 60.78;
H, 4.80; N, 9.61. 1H NMR ($CDCl_3$): δ = 8.74 (s, 1 H); 7.98 (s, 1 H); 7.72 (d, 1 H); 7.26
(m, 3 H); 7.08 (d, 1 H); 6.91 (m, 3 H); 4.15 (m, 2 H); 4.08 (m, 1 H); 4.00 (m, 2 H); 3.09
10 (m, 2 H); 2.95 (m, 1 H); 2.87 (m, 1 H); 2.16 (br, 2 H, NH and OH). MS (NH_3 Cl): m/e
= 412 ($M + H^+$, 80%); 369 ($M + H^+ - HNCO$, 100%).

Example 1105-[2-(2(S)-Hydroxy-3-phenoxy-propylamino)-ethoxy]-benzo[b]thiophene-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in
15 Example 3.

M.p. 261-262°C.

1H NMR ($DMSO-d_6$): δ = 7.75 (d, 1 H); 7.60 (s, 1 H); 7.41 (m, 1 H); 7.29 (m, 2 H);
7.02 (d, 1 H); 6.96 (m, 3 H); 4.28 (m, 1 H); 4.25 (m, 2 H); 3.98 (m, 2 H); 3.35 (m, 2 H);
3.21 (m, 1 H); 3.17 (m, 1 H). MS (FAB CH_4 Cl): m/e = 388 ($M + H^+$, 80%).

Example 1115-[2-(2(S)-Hydroxy-3-phenoxy-propylamino)-ethoxy]-benzo[b]thiophene-2-carboxylic acid ethyl ester

The title compound was prepared by a procedure similar to that described in
Example 1.

25 M.p. 99-100°C.

1H NMR ($CDCl_3$): δ = 7.93 (s, 1 H); 7.68 (d, 1 H); 7.24 (m, 3 H); 7.07 (d, 1 H); 6.90 (m,
3 H); 4.38 (q, 2 H); 4.12 (m, 3 H); 3.98 (m, 2 H); 3.08 (m, 2 H); 2.94 (m, 1 H); 2.86 (m,
1 H); 2.44 (br, 2 H, NH and OH). MS (NH_3 Cl): m/e = 416 ($M + H^+$, 100%).

Example 112

30 1-[2-(2-[1,2,4]Oxadiazol-3-yl-benzothiazol-6-yloxy)-ethylamino]-3-phenoxy-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in
Example 1.

-83-

M.p. viscous oil at 25°C.

¹H NMR (CDCl₃): d = 8.87 (s, 1 H); 8.10 (d, 1 H); 7.38 (d, 1 H); 7.23 (m, 2 H); 7.15 (d, 1 H); 6.91 (m, 3 H); 4.16 (m, 2 H); 4.08 (m, 1 H); 4.02 (m, 2 H); 3.11 (m, 2 H); 2.96 (d of d, 1 H); 2.86 (d of d, 1 H). MS (FAB CH₄ Cl): m/e = 413 (M + H⁺, 100%).

5

Example 113

1-Phenoxy-3-{2-[2-(1H-tetrazol-5-yl)-benzothiazol-6-yloxy]-ethylamino}-propan-2(S)-ol

The title compound was prepared by a procedure similar to that described in Example 1.

10

M.p. viscous oil at 25°C.

¹H NMR (DMSO-d₆): d = 7.92 (d, 1 H); 7.73 (d, 1 H); 7.30 (m, 2 H); 7.16 (d, 1 H); 6.96 (m, 3 H); 4.40 (m, 2 H); 4.21 (m, 1 H); 4.03 (m, 2 H); 3.54 (m, 2 H); 3.38 (m, 2 H). MS (FAB CH₄ Cl): m/e = 413 (M + H⁺, 50%).

Example 114

15 1-Benzyl-5-(2(R,S)-(2(R,S)-hydroxy-2-tetrazolo(1,5-a)pyridine-6-yl-ethylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester dihydrochloride salt

The title compound was prepared by a procedure similar to that described in Example 2.

M.p. 110-115°C.

20

Example 115

1-Benzyl-5-(2(R,S)-(2(R,S)-hydroxy-2-tetrazolo(1,5-a)pyridine-6-yl-ethylamino)-propyl)-1H-indole-2-carboxylic acid

The title compound was prepared by a procedure similar to that described in Example 3.

25 M.p. 201-205°C.

Analytical calculated for C₂₆H₂₆N₆O•2.25H₂O: C, 61.11; H, 6.02; N, 16.44. Found C, 61.01; H, 5.66; N, 16.70.

Example 116

30 5-(2(R,S)-(2(R,S)-(6-Amino-pyridin-3-yl)-2-hydroxy-ethylamino)-propyl)-1-benzyl-1H-indole-2-carboxylic acid ethyl ester

The title compound was prepared by a procedure similar to that described in Example 2.

M.p. 58-66°C.

-84-

Analytical calculated for $C_{28}H_{32}N_4O_3 \cdot 0.25H_2O$: C, 70.49; H, 6.87; N, 11.74.
Found: C, 70.37; H, 6.94; N, 11.74.

Example 117

5-(2(R,S)-(2(R,S)-(6-Amino-pyridin-3-yl)-2-hydroxy-ethylamino)-propyl)-1-benzyl-1H-indole-
5 2- carboxylic acid hydrochloride salt

The title compound was prepared by a procedure similar to that described in Example 3.

M.p. 58-66°C.

Analytical calculated for $C_{26}H_{28}N_4O_3 \cdot HCl \cdot 1.OH_2O$: C, 62.58; H, 6.26; N, 11.23.
10 Found: C, 62.41; H, 6.25; N, 11.13

Example 118

5-(2(R,S)-(2(R)-Hydroxy-3-phenoxy-propylamino)-propyl)-1-(2-methanesulfonylamino-
benzyl)-1H- indole-2-carboxylic acid


The title compound was prepared by a procedure similar to that described in
15 Example 3.

M.p. 140-150°C.

-85-

CLAIMS

1. A compound of the formula



10

- wherein R¹ is phenyl, $-(CH_2)_n$ -O-phenyl, pyridyl, pyrimidyl or thiazolyl; wherein said phenyl and the phenyl moiety of said $-(CH_2)_n$ -O-phenyl may optionally be substituted with one or more substituents independently selected from hydrogen, (C_1-C_6) alkyl optionally substituted with one or more halo atoms, hydroxy, (C_1-C_6) alkoxy optionally substituted with one or more halo atoms, (C_1-C_6) alkylthio, fluoro, chloro, bromo, iodo, nitro, amino, $-NR^7R^8$ and cyano; and wherein each of the ring carbon atoms of said pyridyl, pyrimidinyl or thiazolyl may optionally be substituted with a substituent independently selected from hydrogen, (C_1-C_6) alkyl optionally substituted with one or more halo atoms, hydroxy, (C_1-C_6) alkoxy optionally substituted with one or more halo atoms, (C_1-C_6) alkylthio, fluoro, chloro, bromo, iodo, nitro, amino, $-NR^7R^8$ and cyano;
- 15
- 20
- R² is hydrogen or (C_1-C_6) alkyl optionally substituted with one or more halo atoms;

R³ is hydrogen, $-(CH_2)_n$ -phenyl, $-(C_1-C_{10})$ alkyl, $-(CH_2)_n$ - NR^7R^8 , $-(CH_2)_n$ -CO₂R², $-(CH_2)_n$ -C(=O)- NR^7R^8 , $-(CH_2)_n$ -OR², $-(CH_2)_n$ -SO₃R², $-(CH_2)_n$ -SO₂-(C₁-C₆)alkyl, $-(CH_2)_n$ -

- 25 SO₂NR⁷R⁸, or a heterocycle selected from $-(CH_2)_n$ -pyridyl, $-(CH_2)_n$ -pyrimidyl, $-(CH_2)_n$ -pyrazinyl, $-(CH_2)_n$ -isoxazolyl, $-(CH_2)_n$ -oxazolyl, $-(CH_2)_n$ -thiazolyl, $-(CH_2)_n$ -(1,2,4-oxadiazolyl), $-(CH_2)_n$ -imidazolyl, $-(CH_2)_n$ -triazolyl and $-(CH_2)_n$ -tetrazolyl; wherein one of the ring nitrogen atoms of said $-(CH_2)_n$ -imidazolyl, $-(CH_2)_n$ -triazolyl and $-(CH_2)_n$ -tetrazolyl may optionally be substituted by (C_1-C_6) alkyl optionally substituted with one or more halo atoms; wherein each of said heterocycles may optionally be substituted on one or more of the ring carbon atoms by respectively, one or more substituents
- 30

-86-

independently selected from (C₁-C₆)alkyl optionally substituted with one or more halo

atoms, halo, nitro, cyano, -(CH₂)_n-NR⁷R⁸, -(CH₂)_n-CO₂R², -(CH₂)_n-C(=O)-NR⁷R⁸, -(CH₂)_n-OR²,

-(CH₂)_n-SO₂R², -(CH₂)_n-SO₂-(C₁-C₆)alkyl, or -(CH₂)_n-SO₂NR⁷R⁸; wherein the phenyl moiety of said -(CH₂)_n-phenyl may optionally be substituted with one or more substituents,

- 5 independently selected from (C₁-C₆)alkyl optionally substituted with one or more halo atoms, hydroxy, (C₁-C₆)alkoxy optionally substituted with one or more halo atoms, (C₁-C₆)alkylthio, fluoro, chloro, bromo, iodo, cyano, nitro, -(CH₂)_n-NR⁷R⁸, -(CH₂)_n-CO₂R²,

-(CH₂)_n-C(=O)-NR⁷R⁸, -(CH₂)_n-OR², -(CH₂)_n-SO₃R², -(CH₂)_n-SO₂-(C₁-C₆)alkyl,

- 10 -(CH₂)_n-SO₂NR⁷R⁸, -(CH₂)_n-N(R²)-SO₂-R² wherein each R² is selected independently of the

other R² and -(CH₂)_n-N(R²)-SO₂-NR⁷R⁸;

- 15 R⁴ is -(CH₂)_n-CN, -(CH₂)_n-CO₂R², -(CH₂)_n-SO₃R², -(CH₂)_n-SO₂-(C₁-C₆)alkyl, -(CH₂)_n-SO₂-NR⁷R⁸, -(CH₂)_n-CH₂OH optionally substituted with a suitable protecting group, -(CH₂)_n-CHO, -(CH₂)_n-C(=O)R², -(CH₂)_n-C(=O)NR⁷R⁸, or a heterocycle selected from -(CH₂)_n-thiazolyl, -(CH₂)_n-oxazolyl, -(CH₂)_n-imidazolyl, -(CH₂)_n-triazolyl, -(CH₂)_n-1,2,4-oxadiazolyl, -(CH₂)_n-isoxazolyl, -(CH₂)_n-tetrazolyl and -(CH₂)_n-pyrazolyl; wherein one of
- 20 the ring nitrogen atoms of said -(CH₂)_n-imidazolyl, -(CH₂)_n-triazolyl and -(CH₂)_n-tetrazolyl may optionally be substituted by (C₁-C₆)alkyl optionally substituted with one or more halo atoms; wherein each of said heterocycles may optionally be substituted on one or more of the ring carbon atoms by respectively, one or more substituents independently selected from hydrogen, (C₁-C₆)alkyl optionally substituted with one or

- 25 more halo atoms, -(CH₂)_n-NR⁷R⁸, -(CH₂)_n-CO₂R², halo, nitro, cyano, -(CH₂)_n-C(=O)-NR⁷R⁸, -(CH₂)_n-OR², -(CH₂)_n-SO₃R², -(CH₂)_n-SO₂-(C₁-C₆)alkyl, or -(CH₂)_n-SO₂NR⁷R⁸;

R⁵ is hydrogen or (C₁-C₆)alkyl optionally substituted with one or more halo atoms;

R⁷ and R⁸ are independently hydrogen, (C₁-C₆)alkyl optionally substituted with one or more halo, (C₁-C₈)alkoxy(C₁-C₆)alkyl or (C₃-C₈)cycloalkyl, or R⁷ and R⁸, together with the nitrogen to which they are attached, form a saturated heterocyclic ring having from 3 to 7 carbon atoms wherein one of said carbon atoms may optionally be
5 replaced by oxygen, nitrogen or sulfur;

n is an integer from zero to six;

X is a direct link, oxygen or sulfur;

Y is oxygen, nitrogen or sulfur; and

Z is carbon or nitrogen; with the proviso that: (a) when Y is oxygen or sulfur, R³
10 is absent, and (b) when Z is nitrogen, R⁵ is absent;

or a pharmaceutically acceptable pro-drug of such compound,

or a pharmaceutically acceptable salt of such compound or pro-drug.

2. A compound according to claim 1, wherein R¹ is -(CH₂)_n-O-phenyl optionally substituted with one or more substituents independently selected from
15 hydrogen, (C₁-C₆)alkyl optionally substituted with one or more halo atoms, hydroxy, (C₁-C₆)alkoxy, (C₁-C₆)alkylthio, amino, fluoro, chloro, bromo and iodo.

3. A compound according to claim 1, wherein R¹ is phenyl optionally substituted with one or more substituents independently selected from hydrogen, (C₁-C₆)alkyl optionally substituted with one or more halo atoms, hydroxy, (C₁-C₆)alkoxy
20 optionally substituted with one or more halo atoms, (C₁-C₆)alkylthio, amino, fluoro, chloro, bromo and iodo.

4. A compound according to claim 1, wherein R¹ is pyridyl wherein one or more of the ring carbon atoms may independently be substituted with hydrogen, (C₁-C₆)alkyl optionally substituted with one or more halo atoms, hydroxy, (C₁-C₆)alkoxy
25 optionally substituted with one or more halo atoms, (C₁-C₆)alkylthio, amino, fluoro, chloro, bromo and iodo.

5. A compound according to claim 1 wherein R¹ is phenyl, -(CH₂)_n-O-phenyl or pyridyl; wherein said phenyl and the phenyl moiety of said -(CH₂)_n-O-phenyl may optionally be substituted with one or more substituents; wherein one or more of the
30 carbon atoms of said pyridyl may optionally be substituted; and wherein said substituents are optionally halogen, amino or hydroxy.

6. A compound according to claim 1, wherein x is oxygen.

7. A compound according to claim 2, wherein X is oxygen.

-88-

8. A compound according to claim 3, wherein X is oxygen.
9. A compound according to claim 4, wherein X is oxygen.
10. A compound according to claim 5, wherein X is oxygen.
11. A compound according to claim 1, wherein X is a direct link.
- 5 12. A compound according to claim 2, wherein X is a direct link.
13. A compound according to claim 3, wherein X is a direct link.
14. A compound according to claim 4, wherein X is a direct link.
15. A compound according to claim 5, wherein X is a direct link.
16. A compound according to claim 6, wherein R⁴ is -CO₂CH₃, -CO₂H,
10 -C(=O)CH₃, nitrile (-C≡N), or a heterocycle selected from 3-1,2,4-oxadiazolyl,
5-methyl-1,2,4-oxadiazolyl, 3-isoxazolyl, 3-5-methyl-isoxazolyl, 4-(2-methyl(thiazolyl)),
3-methyl-1,2,4-oxadiazolyl and 5-1,2,4-oxadiazolyl.
17. A compound according to claim 1, wherein R⁴ is -CO₂R².
18. A compound according to claim 13, wherein R⁴ is -CO₂R².
- 15 19. A compound according to claim 1, wherein Y is nitrogen.
20. A compound according to claim 2, wherein Y is nitrogen.
21. A compound according to claim 3, wherein Y is nitrogen.
22. A compound according to claim 4, wherein Y is nitrogen.
23. A compound according to claim 10, wherein Y is nitrogen.
- 20 24. A compound according to claim 11, wherein Y is nitrogen.
25. A compound according to claim 12, wherein Y is nitrogen.
26. A compound according to claim 13, wherein Y is nitrogen.
27. A compound according to claim 16, wherein Y is nitrogen.
28. A compound according to claim 12, wherein Y is nitrogen and R³ is
25 hydrogen, methyl, ethyl, phenylmethyl, pyridylmethyl, pyrizinylmethyl or pyrimidyl-
methyl.
29. A compound according to claim 1 wherein R³ is hydrogen, methyl, ethyl,
phenylmethyl, pyrimidylmethyl, pyrizinylmethyl or pyridylmethyl wherein each of said
phenyl, pyrimidyl, pyrizinyl or pyridinyl moieties of said phenylmethyl, pyrimidylmethyl,
30 pyrizinylmethyl, or pyridinylmethyl groups may

R²
|

optionally be substituted by -SO₂-NR⁷R⁸, -N-SO₂-R² wherein each R² is

-89-

5 selected independently of the other R² and $\begin{array}{c} \text{R}^2 \\ | \\ \text{-N-SO}_2\text{NR}^7\text{R}^8 \end{array}$.

30. A compound according to claim 18 wherein R³ is hydrogen, methyl, ethyl, phenylmethyl, pyrimidylmethyl, pyrizinylmethyl or pyridinylmethyl wherein each of said phenyl, pyrimidyl, pyrizinyl or pyridinyl moieties of said phenylmethyl, pyrimidylmethyl, pyrizinylmethyl, or pyridinylmethyl groups may

10 optionally be substituted by $-\text{SO}_2-\text{NR}^7\text{R}^8$, $-\text{N}-\text{SO}_2-\text{R}^2$ wherein each R^2 is

15 R^2
|
selected independently of the other R^2 and $-\text{SO}_2\text{NR}^7\text{R}^8$.

31. A compound according to claim 19 wherein R³ is hydrogen, methyl, ethyl, phenylmethyl, pyrimidylmethyl, pyrizinylmethyl or pyridinylmethyl wherein each of said phenyl, pyrimidyl, pyrizinyl or pyridinyl moieties of said phenylmethyl, pyrimidylmethyl, pyrizinylmethyl, or pyridinylmethyl groups may

optionally be substituted by $-\text{SO}_2-\text{NR}^7\text{R}^8$, $-\text{N}-\text{SO}_2-\text{R}^2$ wherein each R^2 is

25 R^2
|
selected independently of the other R^2 and $-\text{SO}_2\text{NR}^7\text{R}^8$.

32. A compound according to claim 20 wherein R³ is hydrogen, methyl, ethyl, phenylmethyl, pyrimidylmethyl, pyrazinylmethyl or pyridinylmethyl wherein each of said phenyl, pyrimidyl, pyrazinyl or pyridinyl moieties of said phenylmethyl, pyrimidylmethyl, pyrazinylmethyl, or pyridinylmethyl groups may

optionally be substituted by $-\text{SO}_2-\text{NR}^7\text{R}^8$, $-\text{N}-\text{SO}_2-\text{R}^2$ wherein each R^2 is

selected independently of the other R² and -N-SO₂NR⁷R⁸.

33. A compound according to claim 21 wherein R³ is hydrogen, methyl,
40 ethyl, phenylmethyl, pyrimidylmethyl, pyrazinylmethyl or pyridinylmethyl wherein each

-90-

of said phenyl, pyrimidyl, pyrizinyl or pyridinyl moieties of said phenylmethyl, pyrimidylmethyl, pyrizinylmethyl, or pyridinylmethyl groups may

5 optionally be substituted by $\begin{array}{c} \text{R}^2 \\ | \\ -\text{SO}_2-\text{NR}^7\text{R}^8, -\text{N}-\text{SO}_2-\text{R}^2 \end{array}$ wherein each R^2 is

selected independently of the other R^2 and $\begin{array}{c} \text{R}^2 \\ | \\ -\text{N}-\text{SO}_2\text{NR}^7\text{R}^8. \end{array}$

10 34. A compound according to claim 1, wherein said compound is 1-(5-(2-(2-(S)-hydroxy-3-phenoxy-propylamino)-ethoxy)-benzofuran-2-yl)-ethanone.

35. A compound according to claim 1, wherein said compound is 1-(2-(2-isoxazol-3-yl-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol.

15 36. A compound according to claim 1, wherein said compound is 1-(2-(2-(5-methyl-isoxazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol.

37. A compound according to claim 1, wherein said compound is 1-(2-(2-(2-methyl-thiazol-4-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol.

20 38. A compound according to claim 1, wherein said compound is 1-(2-(2-(5-methyl-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol.

39. A compound according to claim 1, wherein said compound is 1-(2-(2-(1,2,4)-oxadiazol-3-yl)-benzofuran-5-yloxy)-ethylamino)-3-phenoxy-propan-2(S)-ol.

25 40. A compound according to claim 1, wherein said compound is 1-benzyl-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid methyl ester, hydrochloride salt.

30 41. A compound according to claim 1, wherein said compound is 1-benzyl-5-(2(R)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1H-indole-2-carboxylic acid.

42. A compound according to claim 1, wherein said compound is 1-benzyl-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester.

35 43. A compound according to claim 1, wherein said compound is 1-benzyl-5-(2(R,S)-(2S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid.

44. A compound according to claim 1, wherein said compound is 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-dimethylsulfamoyl-benzyl)-1H-indole-2-carboxylic acid ethyl ester.

45. A compound according to claim 1, wherein said compound is 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-dimethylsulfamoyl-benzyl)-1H-indole-2-carboxylic acid.

46. A compound according to claim 1, wherein said compound is 1-(4-dimethylsulfamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid ethyl ester.

47. A compound according to claim 1, wherein said compound is 1-(4-dimethylsulfamoyl-benzyl)-5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1H-indole-2-carboxylic acid.

48. A compound according to claim 1, wherein said compound is 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt.

49. A compound according to claim 1, wherein said compound is 5-(2(R,S)-(2-(3-chloro-phenyl)-2(R)-hydroxy-ethylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid.

50. A compound according to claim 1, wherein said compound is 5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid ethyl ester, hydrochloride salt.

51. A compound according to claim 1, wherein said compound is 5-(2(R,S)-(2(S)-hydroxy-3-phenoxy-propylamino)-propyl)-1-(4-methanesulfonylamino-benzyl)-1H-indole-2-carboxylic acid.

52. A compound according to claim 1, wherein said compound is 5-(2(R,S)-(2(R,S)-(6-amino-pyridin-3-yl)-2-hydroxy-ethylamino)-propyl)-1-benzyl-1H-indole-2-carboxylic acid ethyl ester.

53. A compound according to claim 1, wherein said compound is 5-(2(R,S)-(2(R,S)-(6-amino-pyridin-3-yl)-2-hydroxy-ethylamino)-propyl)-1-benzyl-1H-indole-2-carboxylic acid hydrochloride salt.

54. A pharmaceutical composition for treating a condition selected from the group consisting of diabetes, hyperglycemia and obesity in a mammal, comprising an

amount of a compound according to claim 1 effective in treating such condition and a pharmaceutically acceptable carrier.

55. A method of treating a condition selected from the group consisting of diabetes, hyperglycemia and obesity in a mammal, comprising administering to a
5 mammal in need of such treatment an amount of a compound according to claim 1 effective in treating such condition.

56. A pharmaceutical composition for treating a condition selected from the group consisting of diabetes, hyperglycemia and obesity in a mammal, comprising a β_3 -adrenoceptor stimulating amount of a compound according to claim 1 and a
10 pharmaceutically acceptable carrier.

57. A method of treating a condition selected from the group consisting of diabetes, hyperglycemia and obesity in a mammal, comprising administering to a mammal in need of such treatment a β_3 -adrenoceptor stimulating amount of a compound according to claim 1.

15 58. A pharmaceutical composition for increasing the content of lean meat in edible animals, comprising a β_3 -adrenoceptor stimulating amount of a compound according to claim 1 and a pharmaceutically acceptable carrier.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 94/00117

A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 C07D307/85 C07D209/42 C07D209/22 C07D333/70 C07D401/12
C07D413/04 C07D417/04 C07D417/12 A61K31/40

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| A | EP,A,0 092 450 (SANOFI) 26 October 1983 see page 1 - page 11 --- | 1, 54, 56, 58 |
| A | EP,A,0 156 331 (KAKEN PHARMACEUTICAL) 2 October 1985 see page 1 - page 11; claims --- | 1, 54, 56, 58 |
| A | GB,A,1 268 960 (SANDOZ) 29 March 1972 see page 1 - page 17 --- | 1, 54, 56, 58 |
| A | US,A,3 699 123 (F. SEEMANN ET AL.) 17 October 1972 see column 1 - column 11 ----- | 1, 54, 56, 58 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

11 August 1994

Date of mailing of the international search report

19. 08. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Francois, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/IB 94/00117

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 55,57
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 55,57 are directed to a method of treatment of the a mammal, the search has been carried out and based on the attributed effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 94/00117

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|---|--|
| EP-A-0092450 | 26-10-83 | FR-A- 2523964 CA-A- 1196645 JP-A- 58219160 US-A- 4522824 | 30-09-83 12-11-85 20-12-83 11-06-85 |
| EP-A-0156331 | 02-10-85 | JP-C- 1372732 JP-A- 60202872 JP-B- 61040674 US-A- 4652566 | 07-04-87 14-10-85 10-09-86 24-03-87 |
| GB-A-1268960 | 29-03-72 | NONE | |
| US-A-3699123 | 17-10-72 | BE-A- 764659 CH-A- 530397 DE-A- 2113733 FR-A,B 2085732 GB-A- 1347892 NL-A- 7103859 CH-A- 529753 CH-A- 540252 | 22-09-71 15-11-72 14-10-71 31-12-71 27-02-74 28-09-71 31-10-72 28-09-73 |

THIS PAGE BLANK (USPTO)